TITLE PAGE

Manuscript title

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: whole population cohort study in 46 million adults in England

Short Title

COVID-19 vaccines and with major venous, arterial, and thrombocytopenic events

Authors

CVD-COVID-UK consortium

Writing committee

William N Whiteley FRCP (Chair)

Centre for Clinical Brain Sciences, University of Edinburgh

Nuffield Department of Population Health University of Oxford

Samantha Ip PhD

Department of Public Health and Primary Care, University of Cambridge

Jennifer A Cooper PhD

Bristol Population Health Science Institute, University of Bristol

Thomas Bolton PhD

Department of Public Health and Primary Care, University of Cambridge

Spencer Keene MSc

Department of Public Health and Primary Care, University of Cambridge

Venexia Walker PhD

Bristol Medical School: Population Health Sciences, University of Bristol

Rachel Denholm

Bristol Population Health Science Institute, University of Bristol

Ashley Akbari MSc

Population Data Science, Health Data Research UK, Swansea University

Efosa Omigie BEng MSc

NHS Digital

Sam Hollings PhD

NHS Digital

Emanuele Di Angelantonio FRCP

Department of Public Health and Primary Care, University of Cambridge

NIHR Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge

Spiros Denaxas PhD

Institute of Health Informatics, University College London
Angela Wood PhD*
Department of Public Health and Primary Care, University of Cambridge
Jonathan A C Sterne PhD*
Department of Population Health Sciences, University of Bristol
NIHR Bristol Biomedical Research Centre
HDR UK South West
Cathie Sudlow FRSE*
BHF Data Science Centre, Health Data Research UK

*Drs Wood, Sudlow and Sterne contributed equally

Word count:
Abstract: 349
Manuscript: 3637

Corresponding author
Email: william.whiteley@ed.ac.uk
Telephone: 07811113610

ABSTRACT

Background:

Thromboses in unusual locations after the COVID-19 vaccine ChAdOx1-S have been reported. Better understanding of population-level thrombotic risks after COVID-19 vaccination is needed.

Methods:

We analysed linked electronic health records from adults living in England, from 8th December 2020 to 18th March 2021. We estimated incidence rates and hazard ratios (HRs) for major arterial, venous and thrombocytopenic outcomes 1-28 and >28 days after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were performed separately for ages <70 and ≥70 years, and adjusted for age, sex, comorbidities, and social and demographic factors.

Results:

Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during follow-up. Adjusted HRs 1-28 days after ChAdOx1-S, compared with unvaccinated rates, at ages <70 and ≥70 respectively, were 0.97 (95% CI: 0.90-1.05) and 0.58 (0.53–0.63) for venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for arterial thromboses. Corresponding HRs for BNT162b2 were 0.81 (0.74–0.88) and 0.57 (0.53–0.62) for venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for arterial thromboses. HRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines.

Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged <70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33–3.88 and 1.71, 1.35–2.16 respectively), but not after BNT162b2 (0.59, 0.24–1.45 and 1.00, 0.75–1.34) compared with unvaccinated. The corresponding absolute excess risks of ICVT 1-28 days after ChAdOx1-S were 0.9–3 per million, varying by age and sex.

Conclusions:

Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged <70 years were small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults <40 years are needed. For people aged ≥70 years, rates of arterial or venous thrombotic, events were generally lower after either vaccine.

INTRODUCTION

In late February 2021 several groups reported a rare syndrome of thrombosis and thrombocytopenia after vaccination against severe acute respiratory syndrome coronavirus-2 disease 2019 (COVID-19) with ChAdOx1-S (developed by Oxford-AstraZeneca).[1–3] Thromboses were found in unusual sites such as the cerebral venous sinuses, or mesenteric or portal veins. This syndrome, named 'vaccine-induced immune thrombotic thrombocytopenia' (VITT), is probably due to an autoimmune response to platelet factor 4 (PF4) in the absence of exposure to heparin.[1] Whether the risk of common thrombotic illnesses is also increased post-vaccination is uncertain, although there have been reports of post-vaccination ischaemic stroke and intracerebral haemorrhage.[1,3,4]

Estimates of vaccine-associated excess risk based on case reports and routine reporting may be biased if diagnostic thresholds vary between vaccinated and unvaccinated individuals or there is less than population-wide coverage. In England, the National Health Service (NHS) provides almost all healthcare; therefore, linked health care records provide comprehensive, population-wide data on outcomes before and after vaccination.[5] Vaccination in England began on December 8th 2020: the first groups vaccinated were care home residents, then those aged ≥80 years and frontline health and social care workers. Those clinically extremely vulnerable were invited alongside people aged ≥70 years, and those with other co-morbidities aged <65 alongside people aged >65 years. Consequently, individuals vaccinated earlier are expected to have higher rates of venous and arterial events.

We conducted a cohort study using routinely collected, linked health data from multiple sources, covering almost the entire English adult population (>46 million). Associations of ChAdOx1-S and BNT162b2 (developed by Pfizer–BioNTech) with

115 major venous and arterial events and thrombocytopenic haematological outcomes
116 were estimated from the start of the vaccination program to mid-March 2021, before
117 VITT surveillance was widespread.

118 **METHODS**

119 **Population**

120 The study population was adults (aged ≥18 years), alive and registered with an English
121 NHS general practice on December 8th 2020. The data resource[5] includes primary
122 care data (General practice extraction service (GPES) data for Pandemic Planning
123 and Research, GDPPR) from 98% of general practices linked at individual-level to
124 nationwide secondary care data including all NHS hospital admissions (Hospital
125 Episode Statistics (HES) and Secondary Uses Service (SUS) data from 1997
126 onwards), COVID-19 laboratory testing data, COVID-19 vaccination data (NHS
127 England immunisation management system), national community drug dispensing
128 data (NHS BSA Dispensed Medicines from 2018) and death registrations. We
129 accessed and analysed pseudonymised data within NHS Digital's secure, privacy
130 protecting Trusted Research Environment.[6]

131 **Covariates**

132 Covariates were defined from primary care, hospital admissions, community drug
133 dispensing and COVID-19 laboratory testing data, using phenotyping algorithms
134 verified by specialist physicians (see study protocol). Phenotypes for co-morbidities,
135 risk factors and other covariates used Systematized Nomenclature of Medicine
136 Clinical Terms (SNOMED-CT) concepts for primary care data, and ICD-10 codes for
137 hospital admission data. Sex, age, region, deprivation and smoking status were
138 defined as the latest recorded in primary care records before 8th December 2020, and
139 the most recently recorded ethnicity in either primary care or hospital admissions
140 records was used. History of diabetes, depression, obesity, cancer, chronic
141 obstructive pulmonary disease, chronic kidney disease, stroke, MI, DVT or PE, cancer,

142 thrombophilia, liver disease or dementia were defined as any record in primary care
143 and/or hospital admission data before December 8th 2020. The number of unique
144 diseases in SNOMED-CT for the year before December 8th 2020 were derived from
145 primary care records and major surgery in the previous year from hospital admission
146 records (using the Office of Population Censuses and Surveys classification of
147 surgical procedures).

148 A history of coronavirus (SARS-CoV2) infection was defined as either a positive
149 COVID-19 antigen test in national laboratory data covering swab tests performed in
150 the general population and hospitals or a confirmed COVID-19 diagnosis in primary
151 care or hospital admission records. Prior medication was defined using community
152 dispensing data on all prescriptions dispensed by community pharmacists, appliance
153 contractors, and doctors in England. British National Formulary (BNF) codes were
154 used to define the total number of types of medication prescribed and dispensed in
155 the following groups: antiplatelets, antihypertensives, lipid lowering agents, oral
156 anticoagulants, combined oral contraceptives, and hormone replacement therapy.

157 **Outcomes**

158 Outcomes were derived from primary care data, hospital admission data (SUS
159 dataset) and the national death registry (see supplementary material).[7] Specialist
160 clinician-verified SNOMED-CT and ICD-10 rule-based phenotyping algorithms were
161 used to define fatal or non-fatal (i) arterial thrombotic events: myocardial infarction
162 (MI), ischaemic stroke (ischaemic or unclassified stroke, spinal stroke or retinal
163 infarction), other non-stroke non-MI arterial thrombo-embolism; (ii) venous thrombo-
164 embolic events: pulmonary embolism (PE), lower limb deep venous thrombosis (DVT),
165 intracranial venous thrombosis (ICVT), portal vein thrombosis, and venous thrombosis
166 at other sites; (iii) thrombocytopenic haematological events: any thrombocytopenia

167 (idiopathic, primary, secondary or unspecified), disseminated intravascular
168 coagulation (DIC), and thrombotic thrombocytopenic purpura (TTP); (iv) death from
169 any cause; (v) other vascular outcomes: haemorrhagic stroke (intracerebral or
170 subarachnoid), and mesenteric thrombus for which available codes did not distinguish
171 between arterial or venous causes; and (vi) lower limb fracture as a control condition
172 unlikely to be affected by vaccination. The event date was the earliest of: start of
173 hospital episode, death, or recorded date of primary care event or consultation. Events
174 within the death registry were identified based on underlying cause of death and in
175 hospital admission data based on the primary cause of the care episode.

176 **Statistical analyses**

177 Data were analysed according to a pre-specified plan, published on GitHub on April
178 27th 2021.[8] Follow-up was from December 8th 2020 to March 18th 2021, the date the
179 European Medicine Agency (EMA) Pharmacovigilance Risk Assessment Committee
180 (PRAC) discussed the first reported complications of vaccination, after which
181 diagnostic effort is expected to be concentrated in people receiving ChAdOx1-S.[9] Any
182 cell numbers <5 and any potentially disclosive numbers <10 are not reported exactly
183 but as <5 and <10 respectively.

184 Follow up time for each person was split into periods before, and 1-28 and >28 days
185 after, first vaccination. Censoring was at the earliest of the outcome, death, March 18th
186 2021 and, in analyses of specific vaccines, receipt of the other vaccine. Incidence
187 rates per 100,000 people per year were estimated for each outcome, before and 1-28
188 and >28 days after vaccination.

189 Cox models with time zero December 8th 2020 were fitted, ensuring that all analyses
190 accounted for changes in rates of outcome events with calendar time. Hazard ratios

comparing the periods 1-28 and >28 days after vaccination with unvaccinated or pre-vaccination person-time (reference) were estimated. Cox models were fitted separately by age group (<70 and ≥70 years), both overall and separately for males and females. All Cox models were stratified by geographic region. For rare outcomes, sex-specific hazard ratios were estimated from vaccine-sex interaction terms. For computational efficiency, each model included data from all people with, and a 10% random sample of people without, the outcome of interest; analyses incorporated inverse probability weights to account for this sampling. Confidence intervals were derived using robust standard errors.

Region-; age-sex-region-; and fully-adjusted hazard ratios (HR) for associations of ChAdOx1-S and BNT162b2 with outcome events were estimated. The following covariates were included in all fully-adjusted models: (a) sex, age and age^2, ethnicity, postcode-derived deprivation level; (b) risk factors for venous thromboses (anticoagulant medication, combined oral contraceptive medication, hormone replacement therapy medication, history of PE or DVT, and history of coronavirus infection); (c) risk factors for arterial thromboses (diabetes, hypertension, smoking, antiplatelet medication, blood pressure lowering medication, lipid lowering medication, anticoagulant medication, history of stroke, and history of MI); (d) further covariates selected using a backwards stepwise procedure with p value threshold 0.2, from models using MI as outcome (separately in the four groups defined by age and sex). The covariates had few missing values (apart from ethnicity, for which the 5.9% 'missing' were included as a separate category); hence all analyses used "complete-cases".

Sensitivity analyses examined outcome events recorded as the primary or secondary reason for admission or death in hospital admissions or death records; fatal outcome

events (those followed by death from any cause within 28-days); and all venous and all arterial thrombotic outcome events associated with thrombocytopenia. Effect modification by age, sex, ethnicity, medication, diabetes, deprivation and medical history was examined for all venous and all arterial thromboses.

Absolute excess risks of ICVT were estimated by applying estimated hazard ratios to incidence rates of first fatal or non-fatal events in decades of age and sex in 2019, derived from linked hospital and death records.

The study was approved by the Newcastle & North Tyneside 2 Research Ethics Committee (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC-381078-Y9C5K) and the British Heart Foundation Data Science Centre CVD-COVID-UK Approvals and Oversight Board.

Data manipulation and analyses used SQL and Python in Databricks and RStudio (Professional) Version 1.3.1093.1 driven by R Version 4.0.3. All code and phenotypes are available at github.com/BHFDSC/CCU002_02.

RESULTS

On December 8th 2020, 46,162,942 eligible adults were registered with an English general practice. By March 18th 2021, 21,193,814 (46%) had received their first vaccination (8,712,477 BNT162b2; 12,481,337 ChAdOx1-S) (supplementary figure 1). Post-vaccination person-years of follow up for ages <40, 40-69 and ≥70 years respectively were, for ChAdOx1-S: 91,206, 417,160 and 401,343 person years; for BNT162b2: 159,856, 427,874, and 583, 890 person years.

The risks per 100,000 persons from December 8th 2020 to March 18th 2021 were: any venous thrombosis 45.3, any arterial thrombosis 189; thrombocytopenia 4.2 (Table 1). Risks of venous and arterial thromboses were higher in people with co-morbidities and

with increasing age and deprivation, and varied substantially by ethnicity. Absolute and relative increases in risk with increasing age and deprivation were greater for arterial than for venous thromboses. The risk of venous thromboses was higher in people with prior DVT or PE, thrombophilia, or oral anticoagulant medication, while the risk of arterial thromboses was higher in people with prior stroke, MI or antiplatelet medication. The risk of thrombocytopenia increased with age and co-morbidities but varied less markedly with ethnicity and deprivation than the risk of venous or arterial thromboses.

Incidence rates of all events varied substantially in unvaccinated and post-vaccination (Table 2). In the unvaccinated, the crude incidence rates per 100,000 person years were: all venous thromboses 141 (mostly PE and DVT), ICVT 1.97; portal vein thrombosis 1.15; any arterial thrombosis 549 (with slightly more ischaemic stroke (273) than MI (268)); any thrombocytopenia 13, with very low rates of DIC (0.12) and TTP (0.67). For each vaccine, unadjusted incidence rates of venous and arterial thromboses, haemorrhagic stroke, mesenteric thrombus and thrombocytopenia were higher after than before vaccination in the under 70s, but lower after than before vaccination in the over 70s.

The additional confounding factors selected using backward selection were: for both sexes and age strata, previous diagnosis of cancer, number of unique diseases in the last year, surgery in the last year, obesity, liver disease; additionally for women aged <70, history of depression and total number of types of medication (by BNF chapters); additionally for men aged <70, history of SARS-CoV2 infection and thrombocytopenia; and additionally for men and women aged ≥70, chronic kidney disease and dementia.

Crude hazard ratios were substantially attenuated after adjusting for age, and further attenuated after adjusting for confounding factors. For example, in <70 year-olds the

265 HRs 1-28 days post- versus unvaccinated were attenuated from 2.81 to 2.27 for ICVT;
266 from 4.85 to 1.71 for thrombocytopenia; and from 3.21 to 0.90 for ischaemic stroke
267 (supplementary table 1).

268 In people aged <70 years, the fully adjusted HR for any venous thrombosis was 0.97
269 (95% CI:0.90-1.05) 1–28 days after ChAdOx1-S compared with before vaccination,
270 with similar adjusted HRs for PE and DVT. Compared with before vaccination, the
271 hazard of any venous thrombosis was lower 1-28 days after ChAdOx1-S in people
272 aged ≥70 (adjusted HR 0.58, 95%CI:0.53–0.63) and 1–28 days after BNT162b2 (<70:
273 HR 0.81, 0.74–0.88; ≥70 HR: 0.57, 0.53–0.62), with similar adjusted HRs for PE and
274 DVT. (Figure 1, supplementary table 1).

275 In people aged <70 years, adjusted HRs for ICVT were 2.27 (95%CI: 1.32–3.88) 1-28
276 days after ChAdOx1-S and 0.51 (0.16–1.68) 1-28 days after BNT162b2. HRs were
277 similar in men and women. In a post-hoc analyses, in people aged <40 years, the HRs
278 1-28 days after vaccination were 3.73 (1.58–8.83) and 1.07 (0.33–3.48) for ChAdOx1-
279 S and BNT162b2 respectively. The same estimates for people 40-69 years were 1.93
280 (1.19–2.13) and 0.74 (0.29–1.87). In people aged ≥70 years, associations of
281 vaccination with ICVT were estimated imprecisely (<10 events for ChAdOx1-S and 8
282 for BNT162b2 (Figure 1, supplementary table 1).

283 Adjusted HRs for any arterial thrombosis 1-28 days after ChAdOx1-S were 0.90
284 (95%CI: 0.86-0.95) and 0.76 (0.73–0.79) in people aged <70 and ≥70 years
285 respectively. Corresponding HRs 1-28 days after BNT162b2 were 0.94 (0.90-0.99)
286 and 0.72 (0.70–0.75). HRs were similar for MI and ischaemic stroke, and >28 days
287 after vaccination (Figure 2, supplementary table 1).

288 In people aged <70 years, adjusted HRs for thrombocytopenia were 1.71
289 (95%CI:1.35–2.16) 1–28 days and 1.69 (1.16–2.46) >28 days after ChAdOx1-S.
290 Corresponding HRs after BNT162b2 were 1.00 (0.75–1.34) and 0.97 (0.66–1.41). For
291 those aged ≥70 years, adjusted HRs for thrombocytopenia 1-28 days after vaccination
292 were similar for ChAdOx1 (0.79, 95%CI: 0.56–1.10) and BNT162b2 (0.68, 0.51-0.90)
293 (Figure 3, supplementary table 1).

294 Adjusted HRs for lower limb fracture 1–28 days after ChAdOx1-S were 0.85 (95% CI:
295 0.77–0.93), and 0.83 (0.78–0.89) in people aged <70 and ≥70 years respectively.
296 Corresponding HRs after BNT162b2 were 0.93 (0.84–1.02) and 0.69 (0.66–0.73).
297 (Figure 3, supplementary table 1). Adjusted HRs for all-cause mortality 1–28 days after
298 ChAdOx1-S were 0.37 (95%CI: 0.35–0.39), and 0.28 (0.28–0.29) in people aged <70
299 and ≥70 years respectively. Corresponding HRs after BNT162b2 were 0.24 (0.22–
300 0.26) and 0.19 (0.19–0.20) (supplementary figure 2, supplementary table 1).

301 **Subgroup analyses**

302 HRs for all venous and for all arterial thrombotic events 1-28 days after vaccination
303 were lower in older age groups for each vaccine (all interaction p values <0.0001)
304 (supplementary table 2). HRs for venous thromboses were >1 1-28 days after
305 compared with before vaccination in people aged <50 years for ChAdOx1-S but not
306 BNT162b2. HRs for arterial thromboses were >1 1-28 days after compared with before
307 vaccination in people aged <50 years for both ChAdOx1-S and BNT162b2. A higher
308 proportion of venous thromboses in those aged <40 years compared with those aged
309 ≥40 years were due to ICVT. A higher proportion of arterial thromboses at age <40
310 was due to stroke than at ages 40–59 and 60–69 years. Less marked trends for lower
311 HRs in older individuals were observed for HRs >28 days after vaccination. Despite
312 modest differences between the magnitude of HRs in subgroups defined by sex,

313 ethnicity, prior COVID, COCP, diabetes, deprivation or history of MI, DVT or PE,
314 anticoagulation or antiplatelet medication, HRs in all of these subgroups were
315 consistent with lower rates of arterial or venous thromboses after vaccination with
316 ChAdOx1-S or BNT162b2.

317 **Sensitivity analyses**

318 When using a less restrictive outcome definition (outcomes recorded as primary or
319 secondary reason for admission), estimated HRs were consistent with those from
320 analyses of outcomes in the primary position (supplementary figure 3). Similarly,
321 estimated HRs for fatal outcomes, were similar to HRs for outcomes in the primary
322 position (supplementary figure 4). There were very few people for whom outcomes in
323 the primary position were recorded as well as thrombocytopenia in any position in the
324 same hospital admission or death record (after ChAdOx1-S and BNT162b
325 respectively: ICVT 7 and 0; all arterial thromboses 47 and 58; all venous thromboses
326 37 and 26).

327 **Intracranial venous thrombosis**

328 Characteristics were similar among patients who developed ICVT while unvaccinated,
329 after ChAdOx1 and after BNT162b. Most were women (66% unvaccinated, 67%
330 ChAdOx1, 79% BNT162b), of white ethnicity (75% unvaccinated, 92% ChAdOx1,
331 100% BNT162b), and had no prior co-morbidities (71% unvaccinated, 50% ChAdOx1,
332 50% BNT162b). Patients with post vaccination ICVT were older than those with
333 unvaccinated ICVT. Post-vaccination, no patients had a recorded history of
334 thrombophilia, and fewer than 5% had a recorded dispensed prescription of oral
335 contraceptive or HRT (supplementary Table 3).

336 Applying the HR for ICVT 1-28 days after ChAdOx1 to the monthly incidence of ICVT
337 in 2019, the excess risk of ICVT in the month after vaccination with ChAdOx1 among
338 those aged 19–30, 31–39, 40–49, 50–59 and 60–69-years was estimated to be,
339 respectively: 0.9, 1.1, 1.5, 1.5 and 1.6 per million vaccinated in men and 3.0, 2.7, 2.0,
340 1.6 and 1.5 per million vaccinated in women.

341 **DISCUSSION**

342 In this cohort study, which included almost all adults alive in England at the start of the
343 national COVID-19 vaccination programme, vaccination with ChAdOx1-S, but not
344 BNT162b2, was associated with approximately 2-fold higher rates of ICVT or
345 hospitalisations due to thrombocytopenia in people aged under 70 years, after
346 adjusting for a comprehensive range of demographic characteristics and
347 comorbidities. The corresponding absolute increases in the risk of these events were
348 very small. ChAdOx1-S and BNT162b2 were associated with lower hazards of major
349 vascular events after vaccination in those aged ≥70 years. Post-hoc analyses stratified
350 by age suggest that in people aged <50 years, rates of venous thromboses were
351 higher 1-28 days after vaccination with ChAdOx1-S, and that rates of arterial
352 thrombotic events were higher 1-28 days after vaccination with ChAdOx1-S or
353 BNT162b2, compared with rates in unvaccinated people.

354 The large population analysed (including almost 10 times as many vaccinated people
355 as any other published study) adds substantial precision to estimated associations of
356 thromboses with vaccination, which is of particular importance for very rare events and
357 associations in subgroups. The extensive data linkages across different healthcare
358 settings enabled adjustment for a wide range of confounding variables. The analysed
359 population is slightly larger than the mid-year estimate of the 2020 English population

aged ≥18 (44,456,850) that excluded short-term residents and students, and modelled international migrant numbers.[10]

Smaller Danish and Norwegian electronic health record studies reported a small excess of intracranial haemorrhage (2 per 100,000 1–28 days after ChAdOx1-S), cerebral venous thrombosis (3 per 100,000) and other venous thrombosis (2 per 100,000).[11] The randomised trials of ChAdOx1-S, reported no venous thrombotic events among 8597 participants who received the vaccine versus two among 8581who received placebo.[12] A Scottish study found a risk of of 1.13 (0.62–1.63) cases of idiopathic thrombocytopenic purpura per 100,000 after ChAdOx1-S. There was no clear evidence on other outcomes, although the number of post-vaccine events was small.[13] Reporting of ICVT cases to the UK Medicines and Healthcare products Regulatory Agency (MHRA) identified more cases of ICVT with thrombocytopenia after ChAdOx1-S than the present study (44 up to 31st March 2021).[14]

Healthcare systems planning to use ChAdOx1-S should balance the very small harms against the known benefits of the vaccine. For older populations, who are most vulnerable to COVID-19, we found no evidence of increased risk of any event with ChAdOx1-S. In younger populations, who have a lower morbidity and mortality due to COVID-19, other available vaccines might be prioritise, especially when the risk of COVID-19 is otherwise low.

Our study has several limitations. First, identification of exposures, covariates and outcomes relies on the accuracy of data collected during routine healthcare. Additional data on results of laboratory and radiology investigations would have improved diagnostic coding, particularly for ascertainment of thrombocytopenia. Second, people who were not registered with an NHS GP (for example the homeless, recent immigrants, those using only private healthcare and those not eligible for NHS care)

385 or who opted out of their data being provided to NHS Digital were excluded. Third,
386 follow up ended on March 18th 2021, but a small number of events that occurred before
387 this date may have been excluded because they had yet to be coded or the people
388 affected were still in hospital. Analyses after this date will likely lead to overestimation
389 of associations, because speciality societies recommended further investigations of
390 mild symptoms in vaccinated populations. Fourth, our primary outcome used the
391 primary reason for death or hospital admission, which improves the positive predictive
392 value but may lead to an underestimation of incidence. This is necessary because
393 historical non-incident events are frequently recorded in secondary positions.
394 Analyses of events recorded in any position as fatal within 28 days were consistent
395 with the primary analyses. Fifth, we did not address time-varying confounding, which
396 can occur when factors which vary during follow up, such as admission to hospital,
397 predict both vaccination and outcomes of interest. Sixth, comparison of adjusted and
398 unadjusted associations suggests that studies that do not adjust for a comprehensive
399 range of potential confounders will overestimate the thrombotic effects of vaccination.
400 However, adjusted associations in this study may still be biased by unmeasured
401 confounding by patient characteristics that predict both vaccination and thromboses
402 and that are difficult to ascertain in electronic health records. Examples include general
403 health at the time of vaccination, and people at higher risk of thromboses (e.g. with
404 end-stage diseases).[15] There were slightly lower post-vaccination rates of the
405 'negative control' outcome lower limb fracture in those aged ≥70 years, which implies
406 that this degree of unmeasured confounding may affect results for thrombotic
407 outcomes in that age group.

408 Associations of vaccination with thromboses varied with age. This may be because in
409 older people small increases in the risk of major thrombotic events after vaccination

410 with ChAdOx1-S were more than offset by reductions in major thrombotic events
411 (particularly PE) subsequent to COVID-19. By contrast, in younger people any
412 increase in risk associated with ChAdOx1-S vaccine is less likely to be offset by a
413 lower risk of COVID-associated thrombosis, because the chance of severe COVID
414 disease is lower in younger than older individuals.

415 Further analyses assessing the effects of other vaccines and the effects of second
416 doses of these vaccines on thrombotic, neurological and cardiac complications will be
417 important to inform vaccination programs. Access to data from radiology or laboratory
418 systems (which in the UK will rely on regional rather than national data collection
419 systems) will allow more comprehensive case ascertainment and more granular
420 phenotyping. Such efforts are currently underway across the UK.

DATA SHARING

The de-identified data used in this study is available via the CVD-COVID-UK consortium coordinated by BHF Data Science Centre (https://www.hdruk.ac.uk/projects/cvd-covid-uk-project/) for accredited researchers working on approved projects in the NHS Digital trusted research environment. The study protocol, analytic and phenotyping code is available at: https://github.com/BHFDSC/CCU002_02

FUNDING

The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS Digital) of the trusted research environment, provision of linked datasets, data access, user software licences, computational usage, and data management and wrangling support. Support was also provided through the Data and Connectivity and Longitudinal Health and Wellbeing National Core Studies, which were established through the UK Government's Chief Scientific Adviser's National Core Studies programme to coordinate COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians.

WW is supported by the Chief Scientist's Office (CAF/01/17). CS, AW and WW are supported by Stroke Association (SA CV 20\100018). WW has given expert testimony to UK courts.

AMW is supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005) and by core funding from UK MRC (MR/L003120/1), BHF (RG/13/13/30194; RG/18/13/33946), and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). AMW is part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

JAC, JS, and RD are supported by the Health Data Research (HDR) UK South West Better Care Partnership, and the NIHR Bristol Biomedical Research Centre at University Hospitals Bristol, and Weston NHS Foundation Trust and the University of Bristol.

VMW is supported by the Medical Research Council Integrative Epidemiology Unit, which receives its funding from the Medical Research Council and the University of Bristol (MC_UU_00011/4).

AA, SD is supported by Health Data Research UK (grant number: HDR-9006), which receives its funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK, which is funded by the Economic and Social Research Council (grant number: ES/S007393/1).

This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research.

Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication

Conflicts of interest

None

CONTRIBITIONS

WW chaired the writing committee. WW, CS, JS and AW conceived the idea, and prepared the protocol and drafted the manuscript. SI, JAC, SK, VW, TB, RD and JS wrote the analytic code. VW, JAC, SK and SI prepared analytic code for open access publication. SI, VW and TB prepared the tables and figures. EO and SH prepared data from NHS Digital. SD, SK and WW prepared phenotype code. AW and JS designed and supervised the statistical analyses. CS is the Director of the BHF Data Science Centre and coordinated approvals for and access to data within the NHS Digital TRE. All authors commented on the protocol, analyses, and manuscript, and approved the final version before submission. All authors had full access to the study data.

REFERENCES

1 Schultz NH, Sørvoll IH, Michelsen AE, *et al.* Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; published online April 9. DOI:10.1056/nejmoa2104882.

2 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med* 2021; : NEJMoa2104840.

3 Scully M, Singh D, Lown R, *et al.* Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; : NEJMoa2105385.

4 Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas A-M. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. *J Thromb Haemost* 2021; published online April 20. DOI:10.1111/jth.15347.

5 Wood A, Denholm R, Hollings S, *et al.* Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: Data resource. *BMJ* 2021; **373**. DOI:10.1136/bmj.n826.

6 Trusted research environment. https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-environment-service-for-england.

7 Herrett E, Shah AD, Boggon R, *et al.* Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. *BMJ* 2013; **346**: f2350.

8 BHF Data Science Centre. Study protocol. 2021. https://github.com/BHFDSC/Protocols/blob/main/COVID vaccination and risk of arterial and venous event BHF DSC v1.2.pdf.

9 COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - Update | European Medicines Agency. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits (accessed May 10, 2021).

10 Office for National Statistics. Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.

11 Pottegård A, Lund LC, Karlstad Ø, *et al.* Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ* 2021; **373**: n1114.

12 Voysey M, Costa Clemens SA, Madhi SA, *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; **397**: 881–91.

13 Simpson CR, Shi T, Vasileiou E, *et al.* First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nat Med* 2021; published online June 9. DOI:10.1038/s41591-021-01408-4.

14 Hunter PR. Thrombosis after covid-19 vaccination. *BMJ* 2021; **373**. DOI:10.1136/BMJ.N958.

15 OpenSAFELY Collaborative T, Curtis HJ, Inglesby P, *et al.* Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY. *medRxiv* 2021; : 2021.01.25.21250356.

538

539 **TABLES**

540 Table 1 Numbers of patients analysed and (in parentheses) risk per 100,000 of venous
541 and arterial events and thrombocytopenia (TCP) during follow up, overall and
542 according to age.

543 Table 2 Numbers of events and incidence rates pre and post first vaccination.
544 Incidence rate per 100,000 per annum (a) ChAdOx1-S (b) BNT162b2 vaccine

545 **FIGURE LEGENDS**

546

547 **Figure 1** Adjusted Hazard ratios for all venous thromboses, intracranial venous
548 thromboses, pulmonary embolism and deep vein thromboses after ChAdOx1-S or
549 BNT162b2 vaccine.

550 **Figure 2** Adjusted hazard ratios for all arterial thromboses, myocardial infarction,
551 ischaemic stroke and other arterial thromboses after ChAdOx1-S or BNT162b2
552 vaccine.

553 **Figure 3** Adjusted hazard ratios for thrombocytopenia haemorrhagic stroke,
554 mesenteric thrombosis, lower limb fracture after ChAdOx1-S or BNT162b2 vaccine

555 **SUPPLEMENTARY MATERIAL**

556 Protocol

557 **Supplementary table 1** Unadjusted, age-, sex- and region- adjusted, and fully
558 adjusted hazard ratios for (a) ChAdOx1-S (b) BNT162b2 vaccine

559 **Supplementary table 2** Stratum specific estimates for (a) venous and (b) arterial
560 events.

561 **Supplementary table 3**. Characteristics of patient who had an ICVT event before and
562 after vaccination. Only percentage are presented, as disclosure control does not allow
563 numbers <5 to be released

564 **Supplementary figure 1:** Cumulative frequency of vaccines of different types during
565 follow up

566 **Supplementary figure 2**: Adjusted hazard ratios for portal vein thrombosis, other
567 venous events, and death after ChAdOx1-S or BNT162b2 vaccine

568 **Supplementary Figure 3** Hazard ratios for major (A) arterial and (B) venous
569 thrombotic events, and (C) haematological events, other events and lower limb
570 fractures recorded in any position in EHR

571 **Supplementary Figure 4**: Hazard ratios for major (A) arterial and (B) venous
572 thrombotic events, (C) haematological events, other events and fractures recorded in
573 death record or in hospital record in first position followed by death <28 days

Table 1. Numbers of patients analysed and (in parentheses) risk per 100,000 people of venous and arterial events and thrombocytopenia (TCP), overall and according to age.

		Overall				Age, <70				Age, ≥70			
		All	Venous	Arterial	TCP	All	Venous	Arterial	TCP	All	Venous	Arterial	TCP
N		46,162,942	20,903 (45.3)	87,251 (189)	1,926 (4.2)	38,744,171	11,835 (30.5)	38,283 (98.8)	1,167 (3.0)	7,418,771	9,068 (122)	48,968 (660)	759 (10.2)
Sex	Male	22,765,779	10,358 (45.5)	51,851 (228)	986 (4.3)	19,425,454	6,406 (33.0)	26,549 (137)	555 (2.9)	3,340,325	3,952 (118)	25,302 (757)	431 (12.9)
	Female	23,397,163	10,545 (45.1)	35,400 (151)	940 (4.0)	19,318,717	5,429 (28.1)	11,734 (60.7)	612 (3.2)	4,078,446	5,116 (125)	23,666 (580)	328 (8.0)
Age	18 - 29	8,821,973	781 (8.9)	400 (4.5)	143 (1.6)	8,821,973	781 (8.9)	400 (4.5)	143 (1.6)				
	30 - 49	16,131,025	3,544 (22.0)	6,424 (39.8)	338 (2.1)	16,131,025	3,544 (22.0)	6,424 (39.8)	338 (2.1)				
	50 - 69	13,791,173	7,510 (54.5)	31,459 (228)	686 (5.0)	13,791,173	7,510 (54.5)	31,459 (228)	686 (5.0)				
	70 - 79	4,674,973	4,820 (103)	22,249 (476)	418 (8.9)					4,674,973	4,820 (103)	22,249 (476)	418 (8.9)
	80+	2,743,798	4,248 (155)	26,719 (974)	341 (12.4)					2,743,798	4,248 (155)	26,719 (974)	341 (12.4)
Ethnicity	Asian or Asian British	3,718,442	599 (16.1)	5,325 (143)	152 (4.1)	3,467,223	475 (13.7)	3,378 (97.4)	125 (3.6)	251,219	124 (49.4)	1,947 (775)	27 (10.7)
	Black or Black British	1,634,470	654 (40.0)	2,086 (128)	58 (3.5)	1,525,603	513 (33.6)	1,384 (90.7)	45 (2.9)	108,867	141 (130)	702 (645)	13 (11.9)
	Mixed	712,534	182 (25.5)	642 (90.1)	22 (3.1)	682,037	153 (22.4)	426 (62.5)	19 (2.8)	30,497	29 (95.1)	216 (708)	<5 (9.8)
	Other ethnic groups	1,497,133	217 (14.5)	1,072 (71.6)	39 (2.6)	1,427,187	162 (11.4)	678 (47.5)	33 (2.3)	69,946	55 (78.6)	394 (563)	<10 (8.6)
	White	36,446,855	18,995 (52.1)	77,118 (212)	1,643 (4.5)	29,619,868	10,362 (35.0)	31,821 (107)	939 (3.2)	6,826,987	8,633 (126)	45,297 (663)	704 (10.3)
	Unknown or missing	2,153,508	256 (11.9)	1,008 (46.8)	12 (0.6)	2,022,253	170 (8.4)	596 (29.5)	6 (0.3)	131,255	86 (65.5)	412 (314)	<10 (4.6)
Deprivation[1]	1 - 2	9,118,746	4,565 (50.1)	18,830 (206)	365 (4.0)	8,069,275	3,064 (38.0)	10,493 (130)	272 (3.4)	1,049,471	1,501 (143)	8,337 (794)	93 (8.9)
	3 - 4	9,567,633	4,105 (42.9)	17,436 (182)	370 (3.9)	8,273,028	2,454 (29.7)	8,370 (101)	234 (2.8)	1,294,605	1,651 (128)	9,066 (700)	136 (10.5)
	5 - 6	9,355,549	4,091 (43.7)	17,642 (189)	392 (4.2)	7,784,840	2,235 (28.7)	7,263 (93.3)	221 (2.8)	1,570,709	1,856 (118)	10,379 (661)	171 (10.9)
	7 - 8	9,076,313	4,146 (45.7)	16,939 (187)	381 (4.2)	7,362,375	2,128 (28.9)	6,334 (86.0)	221 (3.0)	1,713,938	2,018 (118)	10,605 (619)	160 (9.3)
	9 - 10	8,772,902	3,926 (44.8)	16,024 (183)	406 (4.6)	7,000,538	1,908 (27.3)	5,602 (80.0)	210 (3.0)	1,772,364	2,018 (114)	10,422 (588)	196 (11.1)
Smoking status	Current	7,814,045	3,079 (39.4)	16,115 (206)	260 (3.3)	7,287,225	2,492 (34.2)	11,811 (162)	219 (3.0)	526,820	587 (111)	4,304 (817)	41 (7.8)
	Former	10,623,072	6,930 (65.2)	31,768 (299)	581 (5.5)	7,826,062	3,233 (41.3)	11,703 (150)	277 (3.5)	2,797,010	3,697 (132)	20,065 (717)	304 (10.9)
	Never	25,722,494	10,667 (41.5)	38,701 (150)	1,053 (4.1)	21,674,974	5,929 (27.4)	14,346 (66.2)	643 (3.0)	4,047,520	4,738 (117)	24,355 (602)	410 (10.1)
Medical history	Stroke	727,218	1,020 (140)	21,489 (2,955)	104 (14.3)	286,650	323 (113)	8,147 (2,842)	40 (14.0)	440,568	697 (158)	13,342 (3,028)	64 (14.5)
	Myocardial infarction	1,189,182	1,436 (121)	24,212 (2,036)	158 (13.3)	485,506	436 (89.8)	10,486 (2,160)	46 (9.5)	703,676	1,000 (142)	13,726 (1,951)	112 (15.9)
	DVT or PE	603,351	3,263 (541)	4,050 (671)	142 (23.5)	341,788	1,919 (561)	1,377 (403)	76 (22.2)	261,563	1,344 (514)	2,673 (1,022)	66 (25.2)
	Thrombophilia	44,593	146 (327)	202 (453)	23 (51.6)	38,136	126 (330)	144 (378)	21 (55.1)	6,457	20 (310)	58 (898)	<5 (31.0)
	Coronavirus infection[2]	1,284,984	1,131 (88.0)	4,167 (324)	101 (7.9)	1,124,135	576 (51.2)	1,642 (146)	63 (5.6)	160,849	555 (345)	2,525 (1,570)	38 (23.6)
	Diabetes	4,069,412	3,654 (89.8)	25,595 (629)	423 (10.4)	2,460,649	1,509 (61.3)	9,949 (404)	205 (8.3)	1,608,763	2,145 (133)	15,646 (973)	218 (13.6)
	Depression	9,516,020	6,272 (65.9)	24,146 (254)	500 (5.3)	8,040,590	4,077 (50.7)	12,859 (160)	348 (4.3)	1,475,430	2,195 (149)	11,287 (765)	152 (10.3)
	Obesity	10,918,274	8,863 (81.2)	31,194 (286)	679 (6.2)	8,757,004	5,430 (62.0)	15,848 (181)	411 (4.7)	2,161,270	3,433 (159)	15,346 (710)	268 (12.4)
	Cancer	6,609,691	5,674 (85.8)	17,827 (270)	786 (11.9)	4,854,822	2,583 (53.2)	4,462 (91.9)	412 (8.5)	1,754,869	3,091 (176)	13,365 (762)	374 (21.3)
	COPD	1,582,366	2,497 (158)	12,323 (779)	182 (11.5)	714,880	877 (123)	3,839 (537)	76 (10.6)	867,486	1,620 (187)	8,484 (978)	106 (12.2)
	Liver disease	230,243	284 (123)	1,069 (464)	97 (42.1)	173,423	208 (120)	547 (315)	75 (43.2)	56,820	76 (134)	522 (919)	22 (38.7)
	CKD	2,934,107	4,467 (152)	25,816 (880)	526 (17.9)	978,886	1,179 (120)	5,164 (528)	200 (20.4)	1,955,221	3,288 (168)	20,652 (1,056)	326 (16.7)
	Major surgery[3]	3,995,870	5,407 (135)	24,164 (605)	763 (19.1)	2,773,174	2,735 (98.6)	9,898 (357)	440 (15.9)	1,222,696	2,672 (219)	14,266 (1,167)	323 (26.4)
	Dementia	524,293	1,127 (215)	6,073 (1,158)	45 (8.6)	48,821	81 (166)	415 (850)	10 (20.5)	475,472	1,046 (220)	5,658 (1,190)	35 (7.4)
Medications	Antiplatelet	2,510,382	2,814 (112)	36,415 (1,451)	218 (8.7)	1,000,010	747 (74.7)	15,556 (1,556)	65 (6.5)	1,510,372	2,067 (137)	20,859 (1,381)	153 (10.1)
	BP lowering	8,589,860	7,969 (92.8)	55,462 (646)	777 (9.0)	4,286,561	2,779 (64.8)	20,579 (480)	305 (7.1)	4,303,299	5,190 (121)	34,883 (811)	472 (11.0)
	Lipid lowering	6,808,408	5,796 (85.1)	47,859 (703)	564 (8.3)	3,212,600	1,878 (58.5)	19,543 (608)	194 (6.0)	3,595,808	3,918 (109)	28,316 (787)	370 (10.3)
	Anticoagulant	1,338,585	2,278 (170)	12,758 (953)	205 (15.3)	381,588	1,144 (300)	2,773 (727)	57 (14.9)	956,997	1,134 (118)	9,985 (1043)	148 (15.5)
	Oral contraceptive	622,529	138 (22.2)	42 (6.7)	8 (1.3)	622,529	138 (22.2)	42 (6.7)	8 (1.3)				
	HRT	540,722	213 (39.4)	516 (95.4)	16 (3.0)	501,957	185 (36.9)	368 (73.3)	14 (2.8)	38,765	28 (72.2)	148 (382)	<5 (5.2)
Number of diagnoses	0	36,455,307	12,200 (33.5)	38,617 (106)	980 (2.7)	31,819,272	7,612 (23.9)	18,316 (57.6)	643 (2.0)	4,636,035	4,588 (99.0)	20,301 (438)	337 (7.3)
	1 - 5	9,573,068	8,422 (88.0)	46,012 (481)	925 (9.7)	6,872,479	4,137 (60.2)	19,183 (279)	515 (7.5)	2,700,589	4,285 (159)	26,829 (993)	410 (15.2)
	6+	134,567	281 (209)	2,622 (1948)	21 (15.6)	52,420	86 (164)	784 (1496)	9 (17.2)	82,147	195 (237)	1,838 (2,237)	12 (14.6)
Number of medications	0	22,970,920	3,679 (16.0)	9,629 (41.9)	321 (1.4)	22,122,043	3,143 (14.2)	7,258 (32.8)	290 (1.3)	848,877	536 (63.1)	2,371 (279)	31 (3.7)
	1 - 5	20,875,516	12,872 (61.7)	56,255 (269)	1,210 (5.8)	15,618,756	7,203 (46.1)	25,416 (163)	713 (4.6)	5,256,760	5,669 (108)	30,839 (587)	497 (9.5)
	6+	2,316,506	4,352 (188)	21,367 (922)	395 (17.1)	1,003,372	1,489 (148)	5,609 (559)	164 (16.3)	1,313,134	2,863 (218)	15,758 (1,200)	231 (17.6)

[1] Index of Multiple Deprivation deciles where 10 indicates least deprived and 1 indicates most deprived; [2] After 31/12/2019 and prior to 08/12/2020; [3] In the last year.

Table 2(a) Numbers and incidence rates pre-, post-first ChAdOx1-S. Incidence rate per 100,000 person years. Disclosure control prevents presentation of n>5

		Pre vaccination or unvaccinated		Post vaccination ≤28 days		Post vaccination >28 days	
Outcome	**Age**	**N (events)**	**Incidence rate (95%**	**N (events)**	**Incidence rate (95% CI)**	**N (events)**	**Incidence rate (95%**
All venous	All	14769	140.7 (138.5–143.0)	2006	309.0 (295.8–322.9)	995	382.6 (359.6–407.2)
	<70	9892	104.3 (102.2–106.3)	902	219.5 (205.7–234.3)	234	240.6 (211.7–273.5)
	≥70	4877	484.5 (471.1–498.3)	1104	463.4 (436.9–491.6)	761	467.5 (435.4–501.9)
Intracranial venous thrombosis	All	207	1.97 (1.72–2.26)	27	4.16 (2.85–6.06)	9	3.46 (1.80–6.65)
	<70	188	1.98 (1.72–2.29)	22	5.35 (3.52–8.13)	<10	5.14 (2.14–12.35)
	≥70	19	1.89 (1.20–2.96)	5	2.10 (0.87–5.04)	<5	2.45 (0.92–6.54)
Portal vein thrombosis	All	121	1.15 (0.96–1.38)	14	2.16 (1.28–3.64)	9	3.46 (1.80–6.65)
	<70	98	1.03 (0.85–1.26)	9	2.19 (1.14–4.21)	<5	2.06 (0.51–8.22)
	≥70	23	2.28 (1.52–3.44)	5	2.10 (0.87–5.04)	<10	4.30 (2.05–9.01)
Pulmonary embolism	All	8473	80.7 (79.0–82.5)	1203	185.3 (175.1–196.1)	587	225.7 (208.1–244.7)
	<70	5399	56.9 (55.4–58.4)	515	125.3 (114.9–136.6)	134	137.8 (116.3–163.2)
	≥70	3074	305.3 (294.7–316.3)	688	288.7 (267.9–311.1)	453	278.2 (253.7–305.0)
Deep vein thrombosis	All	5664	54.0 (52.6–55.4)	739	113.8 (105.9–122.3)	374	143.8 (129.9–159.1)
	<70	3971	41.9 (40.6–43.2)	345	83.9 (75.5–93.3)	90	92.5 (75.3–113.8)
	≥70	1693	168.1 (160.3–176.3)	394	165.3 (149.8–182.5)	284	174.4 (155.2–195.9)
Other	All	459	4.37 (3.99–4.79)	51	7.85 (5.97–10.33)	30	11.5 (8.1–16.5)
	<70	359	3.78 (3.41–4.20)	34	8.27 (5.91–11.58)	9	9.25 (4.81–17.78)
	≥70	100	9.93 (8.16–12.08)	17	7.13 (4.43–11.47)	21	12.9 (8.4–19.8)
All arterial	All	57602	549.1 (544.7–553.6)	8256	1274.4 (1247.2–1302.1)	4634	1787.0 (1736.3–1839.2)
	<70	31396	331.0 (327.4–334.7)	2993	729.4 (703.8–756.0)	755	777.4 (723.9–834.9)
	≥70	26206	2607.7 (2576.3–2639.5)	5263	2215.7 (2156.7–2276.4)	3879	2391.5 (2317.4–2467.9)
Myocardial infarction	All	28134	268.1 (265.0–271.3)	3814	587.9 (569.6–606.9)	2050	788.9 (755.5–823.8)
	<70	17341	182.8 (180.1–185.5)	1628	396.4 (377.6–416.2)	363	373.4 (336.9–413.9)
	≥70	10793	1072.7 (1052.6–1093.1)	2186	918.3 (880.6–957.6)	1687	1037.3 (988.9–1088.0)
Ischaemic stroke (ischaemic, unknown, retinal and spinal)	All	28639	272.9 (269.8–276.1)	4334	668.2 (648.6–688.4)	2539	977.6 (940.3–1016.4)
	<70	13505	142.4 (140.0–144.8)	1309	318.7 (301.9–336.4)	377	387.8 (350.6–429.0)
	≥70	15134	1504.7 (1480.9–1528.9)	3025	1271.6 (1227.1–1317.7)	2162	1330.4 (1275.5–1387.7)
Other arterial	All	1308	12.5 (11.8–13.2)	189	29.1 (25.2–33.6)	98	37.7 (30.9–45.9)
	<70	775	8.17 (7.61–8.76)	82	19.9 (16.1–24.8)	22	22.6 (14.9–34.3)
	≥70	533	52.9 (48.6–57.6)	107	44.9 (37.1–54.2)	76	46.6 (37.3–58.4)
Other							
Disseminated intravascular coagulation	All	13	0.12 (0.07–0.21)	<5	0.46 (0.15–1.43)	<5	-
	<70	5	0.05 (0.02–0.13)	<5	0.49 (0.12–1.95)	<5	-
	≥70	8	0.79 (0.40–1.59)	<5	0.42 (0.06–2.98)	<5	-
Thrombotic thrombocytopenic purpura	All	70	0.67 (0.53–0.84)	<5	0.62 (0.23–1.64)	<5	0.77 (0.19–3.07)
	<70	64	0.67 (0.53–0.86)	<5	0.73 (0.24–2.26)	<5	2.06 (0.51–8.22)
	≥70	6	0.60 (0.27–1.33)	<5	0.42 (0.06–2.98)	<5	-
Any thrombocytopenia	All	1357	12.9 (12.3–13.6)	200	30.8 (26.8–35.4)	89	34.2 (27.8–42.1)
	<70	915	9.64 (9.04–10.29)	124	30.2 (25.3–36.0)	41	42.1 (31.0–57.2)
	≥70	442	43.9 (40.0–48.2)	76	31.9 (25.5–39.9)	48	29.5 (22.2–39.1)
Haemorrhagic stroke (intra-cerebral or subarachnoid)	All	3747	35.7 (34.6–36.9)	487	75.0 (68.6–82.0)	289	111.1 (99.0–124.6)
	<70	2028	21.4 (20.5–22.3)	157	38.2 (32.7–44.7)	45	46.3 (34.5–62.0)
	≥70	1719	170.7 (162.8–179.0)	330	138.4 (124.3–154.2)	244	149.8 (132.1–169.8)
Mesenteric thrombosis	All	1170	11.1 (10.5–11.8)	171	26.3 (22.7–30.6)	109	41.9 (34.7–50.5)
	<70	531	5.60 (5.14–6.09)	56	13.6 (10.5–17.7)	20	20.6 (13.3–31.9)
	≥70	639	63.5 (58.7–68.6)	115	48.2 (40.2–57.9)	89	54.6 (44.4–67.2)
Lower limb fracture	All	18347	174.9 (172.3–177.4)	2657	409.4 (394.2–425.3)	1632	628.0 (598.3–659.2)
	<70	8732	92.0 (90.1–94.0)	539	131.2 (120.5–142.7)	155	159.4 (136.2–186.5)
	≥70	9615	955.8 (936.9–975.1)	2118	890.0 (852.9–928.7)	1477	908.3 (863.2–955.9)
Death	All	123580	1177.5 (1170.9–1184.1)	16192	2493.1 (2455.0–2531.8)	11738	4510.6 (4429.7–4592.9)
	<70	29802	314.1 (310.5–317.7)	1940	471.9 (451.4–493.4)	897	922.0 (863.6–984.3)
	≥70	93778	9312.7 (9253.3–9372.5)	14252	5978.2 (5880.8–6077.1)	10841	6653.3 (6529.2–6779.7)

Table 2(b) Numbers and incidence rates pre-, post-first BNT162b2. Incidence rate per 100,000 person years. Disclosure control prevents presentation of n>5

		Pre vaccination or unvaccinated		Post vaccination ≤28 days		Post vaccination >28 days	
Outcome	**Age**	**N (events)**	**Incidence rate (95%**	**N (events)**	**Incidence rate (95%**	**N (events)**	**Incidence rate (95%**
All venous	All	14769	140.7 (138.5–143.0)	1546	250.1 (237.9–262.9)	1587	287.0 (273.2–301.5)
	<70	9892	104.3 (102.2–106.3)	548	154.9 (142.4–168.4)	259	110.8 (98.1–125.2)
	≥70	4877	484.5 (471.1–498.3)	998	377.7 (355.0–401.9)	1328	415.9 (394.1–438.9)
Intracranial venous thrombosis	All	207	1.97 (1.72–2.26)	13	2.10 (1.22–3.62)	6	1.08 (0.49–2.41)
	<70	188	1.98 (1.72–2.29)	5	1.41 (0.59–3.39)	<5	1.28 (0.41–3.98)
	≥70	19	1.89 (1.20–2.96)	8	3.03 (1.51–6.05)	<5	0.94 (0.30–2.91)
Portal vein thrombosis	All	121	1.15 (0.96–1.38)	5	0.81 (0.34–1.94)	12	2.17 (1.23–3.82)
	<70	98	1.03 (0.85–1.26)	<5	0.56 (0.14–2.26)	6	2.57 (1.15–5.71)
	≥70	23	2.28 (1.52–3.44)	<5	1.13 (0.37–3.52)	6	1.88 (0.84–4.18)
Pulmonary embolism	All	8473	80.7 (79.0–82.5)	928	150.1 (140.8–160.1)	955	172.7 (162.1–184.0)
	<70	5399	56.9 (55.4–58.4)	306	86.5 (77.3–96.7)	141	60.3 (51.2–71.2)
	≥70	3074	305.3 (294.7–316.3)	622	235.3 (217.6–254.6)	814	254.8 (237.9–273.0)
Deep vein thrombosis	All	5664	54.0 (52.6–55.4)	555	89.8 (82.6–97.6)	590	106.7 (98.4–115.6)
	<70	3971	41.9 (40.6–43.2)	213	60.2 (52.6–68.8)	103	44.1 (36.3–53.5)
	≥70	1693	168.1 (160.3–176.3)	342	129.4 (116.4–143.9)	487	152.4 (139.5–166.6)
Other	All	459	4.37 (3.99–4.79)	55	8.89 (6.83–11.59)	39	7.05 (5.15–9.65)
	<70	359	3.78 (3.41–4.20)	28	7.91 (5.46–11.46)	13	5.56 (3.23–9.58)
	≥70	100	9.93 (8.16–12.08)	27	10.2 (7.0–14.9)	26	8.14 (5.54–11.95)
All arterial	All	57602	549.1 (544.7–553.6)	7960	1289.8 (1261.7–1318.4)	8799	1594.8 (1561.8–1628.5)
	<70	31396	331.0 (327.4–334.7)	2263	640.2 (614.4–667.2)	876	375.1 (351.1–400.8)
	≥70	26206	2607.7 (2576.3–2639.5)	5697	2160.4 (2105.0–2217.2)	7923	2490.0 (2435.7–2545.4)
Myocardial infarction	All	28134	268.1 (265.0–271.3)	3722	602.5 (583.4–622.2)	4023	728.0 (705.9–750.9)
	<70	17341	182.8 (180.1–185.5)	1285	363.3 (344.0–383.7)	489	209.3 (191.6–228.7)
	≥70	10793	1072.7 (1052.6–1093.1)	2437	922.9 (886.9–960.2)	3534	1107.9 (1072.0–1145.1)
Ischaemic stroke (ischaemic, unknown, retinal and spinal)	All	28639	272.9 (269.8–276.1)	4143	670.6 (650.5–691.4)	4702	851.2 (827.2–875.9)
	<70	13505	142.4 (140.0–144.8)	949	268.2 (251.7–285.9)	369	157.9 (142.6–174.9)
	≥70	15134	1504.7 (1480.9–1528.9)	3194	1209.9 (1168.6–1252.6)	4333	1359.3 (1319.4–1400.4)
Other arterial	All	1308	12.5 (11.8–13.2)	156	25.2 (21.6–29.5)	167	30.2 (25.9–35.1)
	<70	775	8.17 (7.61–8.76)	46	13.0 (9.7–17.3)	26	11.1 (7.6–16.3)
	≥70	533	52.9 (48.6–57.6)	110	41.6 (34.5–50.2)	141	44.1 (37.4–52.0)
Other							
Disseminated intravascular coagulation	All	13	0.12 (0.07–0.21)	<5	0.32 (0.08–1.29)	<5	0.36 (0.09–1.45)
	<70	5	0.05 (0.02–0.13)	<5	0.28 (0.04–2.01)	<5	-
	≥70	8	0.79 (0.40–1.59)	<5	0.38 (0.05–2.69)	<5	0.63 (0.16–2.50)
Thrombotic thrombocytopenic purpura	All	70	0.67 (0.53–0.84)	<5	0.65 (0.24–1.72)	<5	0.36 (0.09–1.45)
	<70	64	0.67 (0.53–0.86)	<5	0.85 (0.27–2.63)	<5	0.86 (0.21–3.42)
	≥70	6	0.60 (0.27–1.33)	<5	0.38 (0.05–2.69)	<5	-
Any thrombocytopenia	All	1357	12.9 (12.3–13.6)	136	22.0 (18.6–26.0)	144	26.0 (22.1–30.6)
	<70	915	9.64 (9.04–10.29)	55	15.5 (11.9–20.2)	32	13.7 (9.7–19.4)
	≥70	442	43.9 (40.0–48.2)	81	30.6 (24.6–38.1)	112	35.1 (29.1–42.2)
Haemorrhagic stroke (intra-cerebral or subarachnoid)	All	3747	35.7 (34.6–36.9)	440	71.2 (64.8–78.1)	579	104.7 (96.5–113.5)
	<70	2028	21.4 (20.5–22.3)	93	26.3 (21.4–32.2)	55	23.5 (18.1–30.7)
	≥70	1719	170.7 (162.8–179.0)	347	131.3 (118.2–145.8)	524	164.0 (150.6–178.7)
Mesenteric thrombosis	All	1170	11.1 (10.5–11.8)	161	26.0 (22.3–30.4)	217	39.2 (34.3–44.8)
	<70	531	5.60 (5.14–6.09)	28	7.91 (5.46–11.46)	18	7.70 (4.85–12.22)
	≥70	639	63.5 (58.7–68.6)	133	50.3 (42.4–59.6)	199	62.3 (54.2–71.6)
Lower limb fracture	All	18347	174.9 (172.3–177.4)	2573	416.2 (400.5–432.6)	3176	574.6 (554.9–594.9)
	<70	8732	92.0 (90.1–94.0)	443	125.2 (114.0–137.4)	228	97.6 (85.7–111.1)
	≥70	9615	955.8 (936.9–975.1)	2130	806.2 (772.7–841.2)	2948	923.9 (891.2–957.9)
Death	All	123580	1177.5 (1170.9–1184.1)	9117	1474.4 (1444.4–1504.9)	13935	2518.7 (2477.3–2560.9)
	<70	29802	314.1 (310.5–317.7)	775	218.9 (204.0–234.9)	531	227.2 (208.7–247.4)
	≥70	93778	9312.7 (9253.3–9372.5)	8342	3155.6 (3088.6–3224.1)	13404	4194.8 (4124.4–4266.4)



Figure 1 Adjusted Hazard ratios for all venous thromboses, intracranial venous thromboses, pulmonary embolism and deep vein thromboses after ChAdOx1-S or BNT162b2 vaccine



Figure 2 Adjusted hazard ratios for all arterial thromboses, myocardial infarction, ischemic stroke and other arterial thromboses after ChAdOx1-S or BNT162b2 vaccine



Figure 3 Adjusted hazard ratios for thrombocytopenia hemorrhagic stroke, mesenteric thrombosis, lower limb fracture after ChAdOx1-S or BNT162b2 vaccine

SUPPLEMENTARY TABLES AND FIGURES

Supplementary Table 1: Hazard ratios (95% CIs) for thrombotic and other outcomes 1-28 and >28 days post-vaccination, compared with pre-vaccination rates. All analyses were stratified on geographical region (A) ChAdOx1-S vaccine (B) BNT162b2 vaccine

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
(A) ChAdOx1-S vaccine								
All venous events	<70	Overall	2.33 (2.16–2.51)	1.32 (1.22–1.43)	0.97 (0.90–1.05)	2.74 (2.39–3.14)	1.60 (1.38–1.84)	0.94 (0.81–1.08)
		Men	2.68 (2.41–2.97)	1.33 (1.19–1.49)	1.04 (0.93–1.16)	3.13 (2.54–3.84)	1.52 (1.23–1.89)	0.97 (0.78–1.20)
		Women	2.08 (1.87–2.31)	1.31 (1.17–1.47)	0.96 (0.85–1.07)	2.56 (2.13–3.07)	1.67 (1.38–2.02)	1.02 (0.84–1.23)
	≥70	Overall	0.65 (0.59–0.72)	0.64 (0.59–0.70)	0.58 (0.53–0.63)	0.67 (0.59–0.76)	0.58 (0.52–0.65)	0.49 (0.44–0.55)
		Men	0.65 (0.56–0.76)	0.65 (0.56–0.74)	0.59 (0.51–0.68)	0.70 (0.58–0.84)	0.63 (0.53–0.75)	0.55 (0.46–0.65)
		Women	0.65 (0.58–0.74)	0.64 (0.56–0.71)	0.57 (0.50–0.64)	0.64 (0.54–0.76)	0.54 (0.47–0.64)	0.45 (0.39–0.53)
Intracranial venous thrombosis	<70	Overall	2.81 (1.70–4.64)	2.99 (1.75–5.09)	2.27 (1.33–3.88)	2.37 (0.91–6.12)	2.47 (0.95–6.42)	1.72 (0.66–4.49)
		Men	2.72 (1.15–6.39)	2.58 (0.99–6.74)	2.06 (0.79–5.37)	3.43 (0.74–15.87)	3.37 (0.71–15.90)	2.40 (0.53–10.86)
		Women	2.69 (1.45–5.00)	3.27 (1.74–6.17)	2.24 (1.17–4.31)	1.75 (0.52–5.93)	2.14 (0.63–7.22)	1.47 (0.43–5.04)
	≥70	Overall	0.62 (0.17–2.23)	0.65 (0.19–2.21)	0.67 (0.20–2.18)	1.35 (0.13–13.46)	1.13 (0.14–9.20)	1.11 (0.14–9.02)
		Men	10.8 (3.3–35.8)	8.99 (2.75–29.42)	10.1 (2.7–38.5)	-	-	-
		Women	0.27 (0.05–1.42)	0.29 (0.06–1.43)	0.28 (0.06–1.34)	0.87 (0.10–7.32)	0.82 (0.11–6.24)	0.76 (0.10–5.70)
Portal vein thrombosis	<70	Overall	2.49 (1.20–5.14)	1.56 (0.72–3.40)	1.00 (0.24–4.15)	2.76 (0.73–10.51)	1.99 (0.53–7.52)	1.00 (0.06–18.18)
		Men	3.38 (1.40–8.17)	1.95 (0.76–5.02)	1.22 (0.48–3.08)	3.55 (0.52–24.13)	2.16 (0.32–14.52)	0.98 (0.14–6.75)
		Women	1.74 (0.48–6.26)	1.06 (0.28–4.07)	0.72 (0.18–2.86)	2.39 (0.37–15.53)	1.57 (0.24–10.12)	0.86 (0.12–6.28)
	≥70	Overall	0.66 (0.11–4.06)	0.67 (0.10–4.24)	0.61 (0.10–3.71)	2.72 (0.49–15.02)	3.00 (0.48–18.99)	2.61 (0.41–16.52)
		Men	0.43 (0.09–2.09)	0.42 (0.08–2.15)	0.37 (0.07–1.90)	8.60 (2.33–31.70)	7.99 (1.93–33.03)	7.99 (2.03–31.38)
		Women	0.92 (0.06–13.23)	0.92 (0.06–13.99)	0.82 (0.06–11.05)	0.87 (0.12–6.02)	0.95 (0.12–7.39)	0.86 (0.11–6.92)
Pulmonary embolism	<70	Overall	2.54 (2.30–2.80)	1.28 (1.15–1.43)	0.95 (0.85–1.05)	3.12 (2.61–3.73)	1.63 (1.34–1.96)	0.95 (0.79–1.15)
		Men	2.83 (2.46–3.24)	1.27 (1.09–1.48)	1.01 (0.87–1.17)	3.32 (2.52–4.38)	1.43 (1.07–1.91)	0.92 (0.69–1.23)
		Women	2.35 (2.04–2.70)	1.30 (1.12–1.52)	0.95 (0.82–1.10)	3.09 (2.44–3.92)	1.81 (1.41–2.32)	1.09 (0.85–1.41)
	≥70	Overall	0.62 (0.55–0.70)	0.60 (0.54–0.68)	0.54 (0.48–0.61)	0.61 (0.52–0.72)	0.54 (0.46–0.62)	0.45 (0.39–0.53)
		Men	0.63 (0.52–0.75)	0.62 (0.52–0.74)	0.57 (0.47–0.67)	0.63 (0.50–0.79)	0.57 (0.46–0.70)	0.49 (0.40–0.62)
		Women	0.61 (0.52–0.72)	0.59 (0.51–0.69)	0.53 (0.45–0.61)	0.60 (0.48–0.75)	0.51 (0.42–0.63)	0.43 (0.35–0.53)
Deep vein thrombosis	<70	Overall	2.08 (1.85–2.34)	1.34 (1.18–1.52)	0.99 (0.87–1.12)	2.37 (1.90–2.96)	1.58 (1.25–1.99)	0.97 (0.77–1.22)
		Men	2.61 (2.22–3.07)	1.48 (1.25–1.76)	1.15 (0.97–1.36)	2.85 (2.04–3.98)	1.62 (1.14–2.29)	1.06 (0.75–1.50)
		Women	1.67 (1.40–2.00)	1.21 (1.00–1.46)	0.90 (0.75–1.09)	2.12 (1.57–2.86)	1.57 (1.15–2.13)	1.02 (0.75–1.40)
	≥70	Overall	0.73 (0.62–0.86)	0.71 (0.61–0.83)	0.63 (0.54–0.74)	0.71 (0.57–0.88)	0.62 (0.51–0.75)	0.51 (0.42–0.62)
		Men	0.72 (0.56–0.94)	0.71 (0.55–0.91)	0.63 (0.49–0.81)	0.77 (0.56–1.06)	0.70 (0.51–0.95)	0.58 (0.42–0.79)
		Women	0.73 (0.59–0.90)	0.72 (0.59–0.87)	0.64 (0.53–0.77)	0.67 (0.51–0.88)	0.57 (0.45–0.73)	0.47 (0.37–0.60)
Other	<70	Overall	2.48 (1.70–3.62)	1.60 (1.06–2.40)	1.02 (0.69–1.52)	3.04 (1.54–6.00)	2.04 (1.01–4.09)	0.94 (0.47–1.91)
		Men	2.61 (1.51–4.53)	1.45 (0.79–2.64)	1.02 (0.57–1.83)	3.17 (1.13–8.90)	1.74 (0.60–5.05)	0.89 (0.31–2.58)
		Women	2.38 (1.42–4.00)	1.74 (1.01–2.98)	1.12 (0.65–1.91)	3.15 (1.29–7.73)	2.40 (0.97–5.96)	1.26 (0.50–3.17)
	≥70	Overall	0.46 (0.21–1.01)	0.46 (0.21–0.99)	0.43 (0.20–0.92)	1.13 (0.50–2.54)	1.03 (0.48–2.21)	0.93 (0.42–2.03)
		Men	0.38 (0.11–1.30)	0.39 (0.12–1.31)	0.33 (0.10–1.08)	1.10 (0.36–3.39)	1.02 (0.34–3.04)	0.79 (0.26–2.36)
		Women	0.52 (0.19–1.44)	0.51 (0.20–1.36)	0.50 (0.19–1.32)	1.16 (0.37–3.63)	1.03 (0.36–2.98)	0.98 (0.33–2.94)

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
All arterial events	<70	Overall	3.02 (2.90–3.14)	1.25 (1.20–1.31)	0.90 (0.86–0.95)	3.55 (3.29–3.83)	1.57 (1.45–1.70)	0.91 (0.84–1.00)
		Men	3.42 (3.26–3.60)	1.26 (1.20–1.34)	0.91 (0.86–0.96)	4.70 (4.27–5.17)	1.66 (1.50–1.84)	0.96 (0.86–1.07)
		Women	2.96 (2.76–3.18)	1.24 (1.14–1.34)	0.93 (0.86–1.00)	3.30 (2.90–3.75)	1.43 (1.25–1.64)	0.88 (0.77–1.02)
	≥70	Overall	0.89 (0.85–0.93)	0.84 (0.80–0.87)	0.76 (0.73–0.79)	1.03 (0.97–1.10)	0.83 (0.78–0.87)	0.72 (0.68–0.77)
		Men	0.90 (0.85–0.96)	0.87 (0.82–0.92)	0.78 (0.74–0.83)	1.06 (0.97–1.16)	0.89 (0.82–0.96)	0.78 (0.71–0.85)
		Women	0.88 (0.82–0.94)	0.80 (0.76–0.85)	0.73 (0.69–0.78)	1.02 (0.93–1.12)	0.77 (0.71–0.83)	0.68 (0.62–0.74)
Myocardial infarction	<70	Overall	2.85 (2.70–3.01)	1.24 (1.17–1.32)	0.88 (0.83–0.94)	2.93 (2.63–3.26)	1.40 (1.24–1.56)	0.83 (0.73–0.93)
		Men	3.23 (3.02–3.44)	1.25 (1.17–1.35)	0.89 (0.83–0.95)	3.52 (3.08–4.03)	1.33 (1.15–1.53)	0.78 (0.68–0.90)
		Women	2.93 (2.63–3.26)	1.22 (1.09–1.38)	0.92 (0.82–1.04)	3.56 (2.95–4.29)	1.58 (1.29–1.92)	1.01 (0.82–1.24)
	≥70	Overall	0.86 (0.80–0.92)	0.83 (0.78–0.88)	0.76 (0.71–0.81)	0.97 (0.89–1.07)	0.83 (0.76–0.90)	0.74 (0.68–0.81)
		Men	0.88 (0.80–0.96)	0.85 (0.78–0.93)	0.77 (0.71–0.84)	0.96 (0.84–1.09)	0.84 (0.74–0.94)	0.73 (0.64–0.82)
		Women	0.85 (0.76–0.94)	0.80 (0.72–0.88)	0.76 (0.69–0.84)	1.03 (0.90–1.19)	0.82 (0.72–0.93)	0.78 (0.68–0.88)
Ischaemic stroke[4]	<70	Overall	3.21 (3.02–3.41)	1.25 (1.17–1.34)	0.90 (0.84–0.96)	4.36 (3.91–4.86)	1.76 (1.56–1.98)	0.94 (0.84–1.07)
		Men	3.73 (3.44–4.05)	1.28 (1.17–1.40)	0.91 (0.83–0.99)	6.58 (5.73–7.57)	2.14 (1.84–2.49)	1.12 (0.96–1.31)
		Women	2.91 (2.64–3.20)	1.21 (1.09–1.35)	0.90 (0.81–1.00)	3.10 (2.59–3.71)	1.32 (1.09–1.59)	0.77 (0.63–0.94)
	≥70	Overall	0.92 (0.87–0.98)	0.85 (0.81–0.90)	0.77 (0.73–0.82)	1.08 (0.99–1.18)	0.83 (0.77–0.90)	0.72 (0.67–0.78)
		Men	0.94 (0.85–1.03)	0.89 (0.82–0.96)	0.81 (0.74–0.88)	1.14 (1.01–1.30)	0.93 (0.83–1.04)	0.82 (0.73–0.92)
		Women	0.92 (0.84–1.00)	0.82 (0.77–0.89)	0.75 (0.69–0.80)	1.04 (0.92–1.17)	0.76 (0.68–0.84)	0.66 (0.59–0.73)
Other arterial	<70	Overall	3.18 (2.48–4.07)	1.24 (0.93–1.64)	0.82 (0.63–1.07)	4.20 (2.62–6.73)	1.68 (0.99–2.86)	0.77 (0.46–1.30)
		Men	3.17 (2.29–4.40)	1.05 (0.73–1.51)	0.75 (0.53–1.07)	5.56 (3.07–10.06)	1.66 (0.86–3.20)	0.89 (0.47–1.69)
		Women	3.67 (2.51–5.37)	1.59 (1.03–2.46)	1.04 (0.68–1.59)	3.60 (1.64–7.91)	1.74 (0.73–4.18)	0.83 (0.35–2.01)
	≥70	Overall	0.44 (0.33–0.59)	0.45 (0.34–0.59)	0.41 (0.31–0.53)	0.55 (0.38–0.79)	0.49 (0.35–0.70)	0.44 (0.31–0.63)
		Men	0.46 (0.31–0.67)	0.45 (0.31–0.66)	0.42 (0.29–0.61)	0.61 (0.35–1.05)	0.56 (0.33–0.95)	0.51 (0.30–0.87)
		Women	0.43 (0.28–0.66)	0.44 (0.30–0.67)	0.39 (0.26–0.59)	0.51 (0.30–0.86)	0.44 (0.27–0.71)	0.38 (0.23–0.62)
Haematological events								
Any thrombocytopenia	<70	Overall	4.85 (3.87–6.07)	3.00 (2.34–3.85)	1.71 (1.35–2.16)	7.48 (5.31–10.53)	4.68 (3.24–6.77)	1.69 (1.16–2.46)
		Men	6.47 (4.62–9.06)	3.52 (2.42–5.13)	1.85 (1.30–2.63)	13.2 (8.1–21.4)	6.84 (3.99–11.73)	2.02 (1.18–3.44)
		Women	3.81 (2.80–5.17)	2.65 (1.89–3.71)	1.95 (1.40–2.72)	4.59 (2.78–7.58)	3.34 (1.98–5.64)	2.08 (1.22–3.54)
	≥70	Overall	0.92 (0.65–1.29)	0.87 (0.63–1.22)	0.79 (0.56–1.10)	1.14 (0.66–1.95)	0.99 (0.59–1.65)	0.84 (0.50–1.41)
		Men	0.84 (0.53–1.32)	0.79 (0.50–1.22)	0.68 (0.43–1.06)	1.37 (0.64–2.91)	1.17 (0.57–2.38)	0.92 (0.45–1.90)
		Women	1.04 (0.62–1.75)	0.99 (0.61–1.63)	0.93 (0.56–1.54)	1.02 (0.46–2.24)	0.88 (0.42–1.85)	0.80 (0.38–1.70)
Other events								
Haemorrhagic stroke[5]	<70	Overall	2.25 (1.88–2.69)	1.05 (0.86–1.27)	1.00 (0.73–1.37)	2.87 (2.10–3.92)	1.39 (1.00–1.93)	1.00 (0.51–1.95)
		Men	2.68 (2.11–3.41)	1.15 (0.89–1.49)	1.01 (0.78–1.30)	2.86 (1.74–4.71)	1.21 (0.72–2.04)	0.87 (0.52–1.46)
		Women	1.93 (1.48–2.52)	0.93 (0.70–1.24)	0.87 (0.66–1.16)	2.94 (1.95–4.42)	1.47 (0.95–2.27)	1.23 (0.80–1.91)
	≥70	Overall	0.83 (0.69–1.00)	0.78 (0.66–0.92)	0.73 (0.62–0.87)	1.09 (0.84–1.40)	0.84 (0.67–1.04)	0.76 (0.61–0.95)
		Men	0.86 (0.65–1.14)	0.82 (0.64–1.05)	0.79 (0.62–1.01)	1.34 (0.93–1.94)	1.03 (0.75–1.43)	0.97 (0.70–1.34)
		Women	0.81 (0.63–1.03)	0.75 (0.60–0.94)	0.70 (0.56–0.87)	0.92 (0.65–1.30)	0.71 (0.52–0.96)	0.64 (0.47–0.86)

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
Mesenteric thrombosis	<70	Overall	3.25 (2.42–4.37)	1.24 (0.89–1.73)	0.84 (0.61–1.16)	5.47 (3.33–8.99)	2.16 (1.24–3.77)	1.04 (0.60–1.80)
		Men	2.87 (1.72–4.77)	0.98 (0.57–1.71)	0.72 (0.43–1.22)	4.34 (1.59–11.83)	1.42 (0.48–4.25)	0.75 (0.26–2.17)
		Women	3.39 (2.36–4.87)	1.43 (0.94–2.17)	1.01 (0.67–1.52)	5.66 (3.21–9.99)	2.59 (1.36–4.94)	1.40 (0.73–2.69)
	≥70	Overall	0.66 (0.49–0.89)	0.60 (0.46–0.79)	0.53 (0.41–0.70)	0.95 (0.64–1.43)	0.74 (0.52–1.05)	0.62 (0.43–0.89)
		Men	0.65 (0.39–1.09)	0.61 (0.38–0.98)	0.52 (0.32–0.83)	0.81 (0.44–1.49)	0.69 (0.40–1.18)	0.54 (0.31–0.94)
		Women	0.66 (0.46–0.95)	0.60 (0.44–0.84)	0.55 (0.40–0.77)	1.00 (0.60–1.68)	0.76 (0.48–1.20)	0.67 (0.42–1.08)
Lower limb fracture	<70	Overall	1.71 (1.55–1.87)	1.01 (0.91–1.11)	0.85 (0.77–0.93)	2.26 (1.91–2.67)	1.35 (1.13–1.60)	0.98 (0.83–1.17)
		Men	1.35 (1.15–1.58)	0.98 (0.83–1.16)	0.86 (0.73–1.02)	2.22 (1.67–2.93)	1.60 (1.20–2.14)	1.24 (0.93–1.66)
		Women	1.91 (1.70–2.15)	1.03 (0.91–1.16)	0.88 (0.78–0.99)	2.21 (1.80–2.72)	1.25 (1.01–1.55)	0.95 (0.77–1.18)
	≥70	Overall	1.11 (1.02–1.21)	0.94 (0.88–1.01)	0.83 (0.78–0.89)	1.56 (1.39–1.76)	0.95 (0.87–1.04)	0.78 (0.71–0.85)
		Men	1.06 (0.90–1.24)	0.94 (0.83–1.08)	0.84 (0.73–0.95)	1.50 (1.19–1.89)	0.97 (0.81–1.17)	0.81 (0.67–0.97)
		Women	1.11 (1.01–1.22)	0.95 (0.88–1.03)	0.84 (0.77–0.91)	1.51 (1.32–1.73)	0.95 (0.85–1.06)	0.78 (0.70–0.87)
Death	<70	Overall	1.96 (1.87–2.06)	0.60 (0.57–0.63)	0.37 (0.35–0.39)	4.51 (4.20–4.85)	1.41 (1.30–1.53)	0.51 (0.47–0.56)
		Men	2.35 (2.20–2.51)	0.63 (0.58–0.67)	0.44 (0.41–0.47)	6.47 (5.87–7.13)	1.57 (1.40–1.75)	0.75 (0.67–0.85)
		Women	1.69 (1.56–1.82)	0.56 (0.52–0.61)	0.36 (0.33–0.39)	3.48 (3.13–3.89)	1.21 (1.07–1.37)	0.50 (0.44–0.57)
	≥70	Overall	0.35 (0.34–0.36)	0.34 (0.33–0.35)	0.28 (0.28–0.29)	0.49 (0.47–0.51)	0.38 (0.37–0.39)	0.27 (0.26–0.28)
		Men	0.31 (0.30–0.32)	0.32 (0.31–0.33)	0.26 (0.25–0.27)	0.44 (0.42–0.47)	0.37 (0.35–0.38)	0.26 (0.24–0.27)
		Women	0.39 (0.37–0.40)	0.36 (0.35–0.37)	0.30 (0.29–0.31)	0.54 (0.51–0.56)	0.39 (0.38–0.41)	0.29 (0.27–0.30)

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
(B) BNT162b2 vaccine	<70	Overall	1.47 (1.35–1.61)	1.01 (0.93–1.11)	0.81 (0.74–0.88)	1.14 (1.01–1.29)	0.88 (0.77–1.00)	0.73 (0.64–0.83)
All venous events		Men	1.98 (1.75–2.23)	1.15 (1.01–1.30)	0.92 (0.81–1.05)	1.56 (1.28–1.89)	1.02 (0.83–1.25)	0.83 (0.68–1.02)
		Women	1.20 (1.06–1.37)	0.91 (0.80–1.03)	0.74 (0.65–0.84)	1.01 (0.86–1.20)	0.81 (0.69–0.96)	0.70 (0.59–0.83)
	≥70	Overall	0.65 (0.60–0.71)	0.56 (0.52–0.61)	0.57 (0.53–0.62)	0.68 (0.62–0.75)	0.50 (0.46–0.55)	0.50 (0.45–0.55)
		Men	0.67 (0.59–0.76)	0.59 (0.52–0.66)	0.60 (0.53–0.67)	0.75 (0.65–0.87)	0.59 (0.51–0.68)	0.58 (0.50–0.67)
		Women	0.64 (0.58–0.72)	0.54 (0.49–0.60)	0.56 (0.50–0.63)	0.63 (0.56–0.72)	0.45 (0.40–0.51)	0.45 (0.40–0.52)
Intracranial venous thrombosis	<70	Overall	0.76 (0.31–1.85)	0.72 (0.29–1.78)	0.59 (0.24–1.45)	0.65 (0.20–2.13)	0.59 (0.18–1.93)	0.51 (0.16–1.68)
		Men	1.60 (0.50–5.16)	1.39 (0.43–4.49)	1.09 (0.33–3.61)	1.04 (0.14–7.77)	0.92 (0.12–7.05)	0.74 (0.10–5.62)
		Women	0.39 (0.10–1.60)	0.44 (0.11–1.78)	0.37 (0.09–1.52)	0.48 (0.11–2.07)	0.51 (0.12–2.20)	0.45 (0.10–1.95)
	≥70	Overall	1.65 (0.64–4.29)	1.25 (0.48–3.26)	1.43 (0.55–3.75)	1.13 (0.13–9.75)	0.71 (0.08–6.56)	0.88 (0.10–7.52)
		Men	-	-	-	-	-	-
		Women	2.01 (0.69–5.88)	1.45 (0.49–4.26)	1.57 (0.54–4.54)	1.26 (0.13–11.94)	0.73 (0.07–7.29)	0.82 (0.09–7.61)
Portal vein thrombosis	<70	Overall	0.58 (0.15–2.30)	0.44 (0.11–1.72)	0.29 (0.07–1.17)	3.06 (1.29–7.24)	2.84 (1.19–6.74)	2.19 (0.89–5.37)
		Men	1.28 (0.33–4.95)	0.81 (0.21–3.09)	0.51 (0.13–2.04)	-	-	-
		Women	-	-	-	5.30 (1.98–14.22)	4.28 (1.55–11.78)	3.95 (1.39–11.20)
	≥70	Overall	0.49 (0.10–2.28)	0.43 (0.10–1.87)	0.42 (0.09–1.91)	0.67 (0.23–1.97)	0.54 (0.19–1.56)	0.48 (0.17–1.38)
		Men	0.85 (0.17–4.38)	0.55 (0.11–2.66)	0.49 (0.10–2.46)	1.26 (0.36–4.41)	0.70 (0.23–2.17)	0.48 (0.17–1.38)
		Women	0.22 (0.01–3.38)	0.24 (0.01–3.80)	0.26 (0.02–4.47)	0.37 (0.09–1.52)	0.44 (0.10–2.01)	0.46 (0.11–2.04)
Pulmonary embolism	<70	Overall	1.52 (1.36–1.71)	0.99 (0.87–1.11)	0.78 (0.69–0.88)	1.20 (1.02–1.43)	0.89 (0.75–1.06)	0.71 (0.60–0.85)
		Men	1.93 (1.63–2.28)	1.05 (0.88–1.25)	0.85 (0.71–1.01)	1.56 (1.19–2.05)	0.97 (0.74–1.29)	0.77 (0.58–1.03)
		Women	1.32 (1.13–1.56)	0.94 (0.79–1.10)	0.75 (0.64–0.89)	1.10 (0.88–1.37)	0.84 (0.67–1.05)	0.71 (0.57–0.89)
	≥70	Overall	0.61 (0.55–0.68)	0.53 (0.48–0.59)	0.54 (0.49–0.60)	0.61 (0.54–0.69)	0.45 (0.40–0.51)	0.45 (0.39–0.50)
		Men	0.64 (0.55–0.75)	0.56 (0.48–0.65)	0.57 (0.49–0.66)	0.65 (0.54–0.77)	0.50 (0.42–0.59)	0.49 (0.41–0.59)
		Women	0.59 (0.52–0.68)	0.51 (0.44–0.58)	0.52 (0.45–0.60)	0.58 (0.49–0.68)	0.42 (0.36–0.49)	0.42 (0.36–0.49)
Deep vein thrombosis	<70	Overall	1.38 (1.21–1.59)	1.03 (0.89–1.18)	0.82 (0.71–0.95)	1.05 (0.86–1.28)	0.85 (0.69–1.04)	0.73 (0.59–0.89)
		Men	1.93 (1.60–2.33)	1.23 (1.01–1.49)	0.99 (0.81–1.20)	1.55 (1.15–2.10)	1.10 (0.81–1.48)	0.94 (0.69–1.28)
		Women	1.08 (0.88–1.33)	0.87 (0.71–1.08)	0.72 (0.58–0.89)	0.88 (0.67–1.15)	0.74 (0.56–0.97)	0.65 (0.50–0.86)
	≥70	Overall	0.69 (0.60–0.79)	0.58 (0.51–0.67)	0.61 (0.53–0.70)	0.81 (0.69–0.96)	0.59 (0.50–0.70)	0.61 (0.52–0.73)
		Men	0.66 (0.53–0.82)	0.59 (0.48–0.73)	0.61 (0.49–0.76)	0.95 (0.74–1.23)	0.78 (0.60–1.01)	0.80 (0.61–1.05)
		Women	0.71 (0.59–0.85)	0.59 (0.49–0.70)	0.62 (0.52–0.74)	0.72 (0.58–0.90)	0.49 (0.40–0.61)	0.52 (0.41–0.64)
Other	<70	Overall	2.16 (1.47–3.19)	1.60 (1.07–2.37)	1.18 (0.79–1.77)	1.64 (0.93–2.90)	1.34 (0.75–2.40)	1.03 (0.57–1.87)
		Men	3.25 (1.93–5.50)	2.03 (1.16–3.54)	1.46 (0.83–2.57)	2.14 (0.86–5.34)	1.51 (0.59–3.86)	1.03 (0.39–2.70)
		Women	1.48 (0.82–2.65)	1.20 (0.67–2.16)	0.98 (0.54–1.77)	1.55 (0.75–3.21)	1.31 (0.63–2.74)	1.21 (0.57–2.55)
	≥70	Overall	1.13 (0.66–1.94)	0.97 (0.58–1.64)	1.01 (0.60–1.72)	0.86 (0.39–1.88)	0.66 (0.31–1.41)	0.67 (0.30–1.47)
		Men	1.50 (0.77–2.95)	1.25 (0.65–2.42)	1.27 (0.64–2.49)	1.51 (0.50–4.51)	1.09 (0.36–3.34)	1.07 (0.33–3.44)
		Women	0.79 (0.31–2.04)	0.72 (0.30–1.75)	0.75 (0.30–1.85)	0.42 (0.17–1.06)	0.36 (0.15–0.88)	0.36 (0.14–0.91)
All arterial events	<70	Overall	2.21 (2.12–2.31)	1.31 (1.25–1.37)	0.94 (0.90–0.99)	1.45 (1.35–1.55)	1.08 (1.01–1.16)	0.88 (0.82–0.95)
		Men	3.06 (2.90–3.22)	1.44 (1.36–1.52)	0.99 (0.93–1.05)	2.17 (1.99–2.38)	1.19 (1.08–1.31)	0.91 (0.82–1.00)
		Women	1.85 (1.71–1.99)	1.11 (1.02–1.20)	0.92 (0.84–0.99)	1.44 (1.30–1.60)	0.96 (0.86–1.07)	0.91 (0.81–1.02)
	≥70	Overall	0.90 (0.87–0.93)	0.69 (0.66–0.71)	0.72 (0.70–0.75)	1.15 (1.10–1.20)	0.69 (0.66–0.72)	0.71 (0.68–0.74)
		Men	0.96 (0.91–1.00)	0.75 (0.71–0.78)	0.77 (0.73–0.81)	1.17 (1.11–1.25)	0.74 (0.70–0.79)	0.74 (0.70–0.79)
		Women	0.84 (0.80–0.89)	0.63 (0.60–0.66)	0.68 (0.65–0.71)	1.13 (1.06–1.20)	0.64 (0.61–0.68)	0.68 (0.64–0.73)

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
Myocardial infarction	<70	Overall	2.24 (2.12–2.37)	1.39 (1.30–1.47)	0.94 (0.88–1.00)	1.42 (1.29–1.55)	1.14 (1.04–1.26)	0.88 (0.80–0.97)
		Men	3.07 (2.87–3.28)	1.51 (1.40–1.62)	0.97 (0.90–1.05)	1.98 (1.76–2.23)	1.13 (1.00–1.28)	0.81 (0.71–0.93)
		Women	1.94 (1.74–2.17)	1.15 (1.03–1.30)	0.94 (0.83–1.06)	1.78 (1.54–2.05)	1.18 (1.02–1.37)	1.11 (0.95–1.30)
	≥70	Overall	0.93 (0.88–0.98)	0.74 (0.71–0.78)	0.74 (0.70–0.78)	1.19 (1.12–1.27)	0.78 (0.73–0.83)	0.75 (0.70–0.80)
		Men	0.99 (0.92–1.06)	0.81 (0.76–0.86)	0.79 (0.73–0.84)	1.20 (1.10–1.31)	0.82 (0.76–0.89)	0.76 (0.70–0.83)
		Women	0.85 (0.78–0.92)	0.66 (0.61–0.72)	0.69 (0.63–0.74)	1.20 (1.08–1.33)	0.74 (0.67–0.81)	0.74 (0.67–0.82)
Ischaemic stroke[4]	<70	Overall	2.18 (2.05–2.33)	1.23 (1.14–1.31)	0.90 (0.83–0.97)	1.46 (1.32–1.62)	1.00 (0.89–1.11)	0.80 (0.72–0.90)
		Men	3.05 (2.80–3.32)	1.38 (1.26–1.51)	0.95 (0.86–1.05)	2.40 (2.08–2.77)	1.26 (1.09–1.46)	0.91 (0.78–1.07)
		Women	1.76 (1.59–1.96)	1.05 (0.94–1.17)	0.85 (0.76–0.95)	1.18 (1.01–1.38)	0.77 (0.66–0.90)	0.73 (0.61–0.86)
	≥70	Overall	0.88 (0.84–0.93)	0.65 (0.63–0.68)	0.71 (0.68–0.75)	1.13 (1.06–1.19)	0.64 (0.60–0.67)	0.69 (0.66–0.73)
		Men	0.94 (0.88–1.00)	0.71 (0.66–0.75)	0.77 (0.72–0.82)	1.17 (1.07–1.27)	0.69 (0.64–0.75)	0.75 (0.69–0.81)
		Women	0.84 (0.78–0.89)	0.61 (0.58–0.65)	0.68 (0.63–0.72)	1.09 (1.01–1.19)	0.60 (0.56–0.65)	0.66 (0.61–0.71)
Other arterial	<70	Overall	1.72 (1.28–2.31)	0.95 (0.70–1.30)	0.69 (0.50–0.94)	1.63 (1.10–2.43)	1.13 (0.74–1.72)	0.85 (0.55–1.32)
		Men	2.31 (1.58–3.37)	0.99 (0.66–1.49)	0.71 (0.47–1.07)	3.22 (2.02–5.13)	1.56 (0.95–2.58)	1.16 (0.69–1.96)
		Women	1.46 (0.90–2.37)	0.88 (0.54–1.45)	0.69 (0.42–1.15)	0.93 (0.43–1.99)	0.65 (0.30–1.43)	0.59 (0.26–1.33)
	≥70	Overall	0.59 (0.46–0.76)	0.51 (0.40–0.65)	0.52 (0.41–0.67)	0.64 (0.47–0.85)	0.47 (0.35–0.62)	0.46 (0.34–0.62)
		Men	0.49 (0.35–0.69)	0.46 (0.32–0.65)	0.47 (0.33–0.66)	0.52 (0.37–0.74)	0.46 (0.32–0.66)	0.44 (0.31–0.64)
		Women	0.74 (0.51–1.08)	0.59 (0.41–0.84)	0.60 (0.42–0.85)	0.83 (0.50–1.37)	0.50 (0.31–0.79)	0.49 (0.30–0.78)
Haematological events								
Any thrombocytopenia	<70	Overall	2.10 (1.60–2.77)	1.48 (1.11–1.97)	1.00 (0.75–1.34)	2.03 (1.42–2.92)	1.54 (1.07–2.23)	0.97 (0.66–1.41)
		Men	3.31 (2.23–4.91)	2.07 (1.35–3.16)	1.19 (0.78–1.83)	2.95 (1.61–5.42)	2.02 (1.08–3.79)	0.93 (0.49–1.78)
		Women	1.50 (1.01–2.22)	1.17 (0.78–1.74)	0.97 (0.65–1.46)	1.58 (1.00–2.50)	1.32 (0.83–2.08)	1.14 (0.72–1.80)
	≥70	Overall	0.85 (0.64–1.13)	0.72 (0.54–0.95)	0.68 (0.51–0.90)	1.22 (0.87–1.71)	0.90 (0.64–1.25)	0.79 (0.56–1.12)
		Men	0.87 (0.61–1.26)	0.73 (0.51–1.05)	0.68 (0.47–0.97)	1.55 (1.03–2.32)	1.12 (0.75–1.67)	0.95 (0.62–1.46)
		Women	0.82 (0.53–1.29)	0.71 (0.46–1.09)	0.68 (0.44–1.07)	0.84 (0.48–1.48)	0.63 (0.36–1.09)	0.57 (0.32–1.02)
Other events								
Haemorrhagic stroke[5]	<70	Overall	1.39 (1.13–1.71)	0.83 (0.67–1.03)	0.77 (0.62–0.96)	1.31 (1.00–1.73)	0.90 (0.68–1.19)	0.86 (0.65–1.15)
		Men	1.65 (1.22–2.23)	0.86 (0.63–1.18)	0.77 (0.57–1.05)	1.43 (0.89–2.29)	0.86 (0.53–1.40)	0.77 (0.47–1.25)
		Women	1.28 (0.95–1.72)	0.80 (0.59–1.08)	0.78 (0.58–1.05)	1.34 (0.95–1.88)	0.89 (0.62–1.26)	0.92 (0.65–1.31)
	≥70	Overall	0.80 (0.69–0.91)	0.59 (0.52–0.68)	0.65 (0.57–0.74)	1.28 (1.09–1.50)	0.72 (0.62–0.84)	0.80 (0.68–0.94)
		Men	0.82 (0.67–1.01)	0.59 (0.48–0.71)	0.64 (0.52–0.78)	1.45 (1.14–1.83)	0.78 (0.62–0.98)	0.86 (0.68–1.09)
		Women	0.78 (0.65–0.94)	0.60 (0.50–0.72)	0.66 (0.55–0.79)	1.16 (0.93–1.44)	0.68 (0.56–0.84)	0.76 (0.61–0.93)
Mesenteric thrombosis	<70	Overall	1.61 (1.10–2.36)	0.84 (0.56–1.26)	0.65 (0.43–0.97)	1.77 (1.11–2.84)	1.08 (0.66–1.75)	0.83 (0.50–1.37)
		Men	2.91 (1.78–4.75)	1.29 (0.77–2.17)	0.97 (0.57–1.64)	2.21 (0.99–4.94)	1.15 (0.50–2.62)	0.82 (0.35–1.91)
		Women	0.91 (0.49–1.67)	0.55 (0.29–1.03)	0.45 (0.23–0.86)	1.61 (0.90–2.88)	1.09 (0.60–1.98)	0.94 (0.50–1.75)
	≥70	Overall	0.72 (0.57–0.90)	0.54 (0.43–0.67)	0.54 (0.44–0.68)	1.06 (0.81–1.37)	0.61 (0.48–0.78)	0.59 (0.45–0.76)
		Men	0.57 (0.37–0.86)	0.41 (0.27–0.61)	0.42 (0.28–0.62)	0.82 (0.53–1.29)	0.44 (0.29–0.66)	0.42 (0.27–0.65)
		Women	0.80 (0.61–1.04)	0.61 (0.47–0.80)	0.62 (0.48–0.81)	1.18 (0.86–1.63)	0.72 (0.53–0.98)	0.70 (0.51–0.96)
Lower limb fracture	<70	Overall	1.44 (1.31–1.59)	1.03 (0.93–1.14)	0.93 (0.84–1.02)	1.24 (1.08–1.42)	0.95 (0.83–1.09)	0.89 (0.78–1.03)
		Men	1.19 (0.99–1.42)	0.94 (0.78–1.12)	0.85 (0.71–1.02)	0.99 (0.74–1.31)	0.83 (0.62–1.11)	0.80 (0.60–1.07)
		Women	1.49 (1.33–1.67)	1.08 (0.96–1.21)	0.98 (0.87–1.10)	1.27 (1.09–1.48)	1.00 (0.85–1.17)	0.94 (0.80–1.11)
	≥70	Overall	0.99 (0.93–1.05)	0.65 (0.62–0.69)	0.69 (0.66–0.73)	1.48 (1.38–1.59)	0.67 (0.63–0.72)	0.71 (0.66–0.76)
		Men	0.95 (0.85–1.06)	0.58 (0.52–0.64)	0.63 (0.57–0.70)	1.60 (1.40–1.83)	0.65 (0.57–0.73)	0.69 (0.61–0.79)
		Women	1.00 (0.93–1.07)	0.68 (0.64–0.73)	0.72 (0.67–0.77)	1.42 (1.30–1.55)	0.68 (0.63–0.73)	0.71 (0.65–0.77)

Outcome	Age	Sex	1-28 days post-vaccination			>28 days post vaccination s		
			Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]	Unadjusted[1]	Age and sex adjusted[2]	Fully adjusted[3]
Death	<70	Overall	0.74 (0.69–0.79)	0.35 (0.32–0.37)	0.24 (0.22–0.26)	0.91 (0.84–1.00)	0.52 (0.48–0.57)	0.33 (0.30–0.37)
		Men	1.06 (0.97–1.17)	0.39 (0.36–0.43)	0.28 (0.25–0.31)	1.62 (1.44–1.82)	0.69 (0.61–0.79)	0.44 (0.39–0.51)
		Women	0.56 (0.50–0.63)	0.29 (0.26–0.33)	0.22 (0.19–0.25)	0.66 (0.58–0.75)	0.38 (0.34–0.44)	0.28 (0.25–0.33)
	≥70	Overall	0.22 (0.22–0.23)	0.16 (0.16–0.16)	0.19 (0.19–0.20)	0.30 (0.29–0.31)	0.16 (0.16–0.16)	0.19 (0.18–0.19)
		Men	0.23 (0.22–0.24)	0.16 (0.15–0.16)	0.19 (0.18–0.20)	0.33 (0.32–0.34)	0.16 (0.15–0.17)	0.19 (0.18–0.19)
		Women	0.21 (0.20–0.22)	0.16 (0.16–0.17)	0.20 (0.19–0.20)	0.27 (0.26–0.28)	0.16 (0.15–0.17)	0.19 (0.18–0.19)

[1]Stratifed by region
[2]Adjusted for age, age^2, sex and stratified by region
[3]Adjusted for age, age^2, sex, ethnicity, deprivation, smoking and co-morbidities, and stratified by region
[4]Ischaemic stroke: including ischaemic stroke, stroke of uncertain cause, and spinal stroke
[5]Hemorrhagic stroke: including intracranial hemorrhage and subarachnoid hemorrhage

Supplementary table 2 (a) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with venous events 1-28 and >28 days after vaccination, within pre-specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

		ChAdOx1-S vaccine					BNT162b2 vaccine				
		N (Events)	Post vaccination ≤28 days		Post vaccination >28 days		N (Events)	Post vaccination ≤28 days		Post vaccination >28 days	
Subgroup		**3001**	HR (95% CI)[1]	P value	HR (95% CI)[1]	P value	**3133**	HR (95% CI)[1]	P value	HR (95% CI)[1]	P value
Age groups	18-29	40	2.30 (1.63–3.25)	<0.0001	1.29 (0.58–2.90)	0.003	29	0.99 (0.60–1.62)	0.005	0.99 (0.57–1.71)	0.839
	30-39	63	1.33 (1.01–1.75)		0.85 (0.46–1.59)		60	0.90 (0.65–1.25)		0.71 (0.47–1.07)	
	40-49	145	1.32 (1.09–1.61)		1.52 (1.09–2.13)		122	0.96 (0.77–1.21)		0.75 (0.56–1.01)	
	50-59	270	0.93 (0.81–1.07)		1.00 (0.77–1.30)		237	0.78 (0.66–0.92)		0.69 (0.55–0.86)	
	60-69	618	0.87 (0.79–0.96)		0.89 (0.73–1.07)		359	0.78 (0.69–0.89)		0.67 (0.55–0.83)	
	70-79	1124	0.75 (0.69–0.82)		0.79 (0.71–0.88)		823	0.69 (0.62–0.77)		0.73 (0.65–0.82)	
	80-89	546	0.79 (0.69–0.89)		0.73 (0.63–0.84)		1255	0.63 (0.56–0.70)		0.67 (0.61–0.74)	
	>90	195	0.76 (0.62–0.94)		0.75 (0.59–0.95)		248	0.80 (0.65–0.99)		0.67 (0.55–0.81)	
Sex	Male	1338	0.81 (0.75–0.87)	0.029	0.74 (0.66–0.82)	0.005	1423	0.70 (0.64–0.76)	0.150	0.66 (0.60–0.72)	0.024
	Female	1663	0.90 (0.84–0.97)		0.89 (0.81–0.98)		1710	0.75 (0.70–0.81)		0.74 (0.69–0.81)	
Ethnicity	White	2856	0.86 (0.82–0.91)	0.018	0.82 (0.76–0.89)	0.429	2977	0.72 (0.68–0.77)	0.002	0.71 (0.66–0.76)	0.691
	Asian or Asian British	38	0.51 (0.34–0.77)		0.66 (0.38–1.14)		56	0.69 (0.48–0.98)		0.57 (0.38–0.86)	
	Black or Black British	53	0.91 (0.66–1.25)		0.62 (0.35–1.10)		42	0.62 (0.41–0.94)		0.61 (0.39–0.97)	
	Mixed	10	0.47 (0.21–1.06)		0.76 (0.28–2.06)		12	0.74 (0.36–1.51)		0.43 (0.16–1.17)	
	Other Ethnic Groups	17	0.73 (0.37–1.43)		1.63 (0.80–3.32)		23	1.30 (0.75–2.24)		0.94 (0.48–1.84)	
	Unknown	21	1.11 (0.65–1.89)		1.14 (0.50–2.58)		15	0.74 (0.36–1.51)		0.68 (0.32–1.47)	
	Missing	6	2.59 (1.05–6.42)		1.29 (0.18–9.32)		8	3.85 (1.67–8.87)		1.33 (0.33–5.43)	
Deprivation	1-2 (least)	564	0.76 (0.68–0.85)	0.138	0.76 (0.65–0.89)	0.43	489	0.65 (0.57–0.74)	0.095	0.54 (0.47–0.62)	<0.0001
	3-4	560	0.86 (0.77–0.96)		0.80 (0.68–0.93)		576	0.76 (0.67–0.85)		0.70 (0.62–0.80)	
	5-6	625	0.90 (0.81–1.00)		0.82 (0.71–0.96)		606	0.70 (0.62–0.79)		0.67 (0.59–0.76)	
	7-8	632	0.87 (0.78–0.97)		0.80 (0.69–0.93)		687	0.73 (0.65–0.82)		0.71 (0.63–0.80)	
	9-10 (most)	609	0.91 (0.81–1.01)		0.92 (0.79–1.06)		770	0.81 (0.72–0.91)		0.88 (0.79–0.98)	
Prior thrombocytopenia	No	3001	0.86 (0.82–0.91)	0.030	0.82 (0.76–0.89)	0.127	3132	0.73 (0.69–0.78)	0.014	0.71 (0.66–0.75)	0.372
	Yes	0	0.54 (0.35–0.82)		0.54 (0.31–0.93)		<5	0.37 (0.21–0.63)		0.58 (0.38–0.89)	
Prior thrombophilia	No	2986	0.86 (0.81–0.91)	0.093	0.82 (0.76–0.89)	0.130	3116	0.73 (0.69–0.77)	0.254	0.70 (0.66–0.75)	0.924
	Yes	15	0.50 (0.27–0.94)		0.38 (0.14–1.03)		17	0.48 (0.23–0.99)		0.68 (0.34–1.37)	
Prior venous event	No	3001	0.95 (0.90–1.01)	<0.0001	0.96 (0.88–1.05)	<0.0001	3133	0.80 (0.76–0.86)	<0.0001	0.78 (0.73–0.84)	<0.0001
	Yes	0	0.54 (0.48–0.61)		0.42 (0.35–0.50)		0	0.44 (0.38–0.51)		0.44 (0.38–0.51)	
Prior COVID infection	No	2839	0.88 (0.83–0.93)	<0.001	0.85 (0.79–0.93)	<0.0001	3012	0.74 (0.70–0.79)	0.001	0.72 (0.68–0.77)	<0.001
	Yes	162	0.60 (0.49–0.74)		0.49 (0.37–0.64)		121	0.47 (0.36–0.61)		0.45 (0.34–0.58)	
OCP	No	2996	1.15 (0.99–1.35)	0.382	1.03 (0.77–1.39)	0.786	3129	0.84 (0.70–1.00)	0.195	0.77 (0.61–0.97)	0.270
	Yes	5	0.69 (0.22–2.17)		1.26 (0.31–5.09)		<5	0.33 (0.08–1.34)		0.34 (0.08–1.41)	
HRT	No	2972	0.78 (0.73–0.83)	0.514	0.75 (0.69–0.82)	0.532	3112	0.69 (0.65–0.73)	0.554	0.66 (0.62–0.71)	0.949
	Yes	29	0.92 (0.56–1.50)		0.96 (0.45–2.05)		21	0.57 (0.30–1.08)		0.65 (0.34–1.23)	
Anticoagulant	No	2759	0.98 (0.92–1.03)	<0.0001	0.98 (0.90–1.07)	<0.0001	2875	0.84 (0.79–0.89)	<0.0001	0.83 (0.77–0.89)	<0.0001
	Yes	242	0.34 (0.29–0.40)		0.28 (0.22–0.35)		258	0.25 (0.21–0.31)		0.27 (0.22–0.32)	
Antiplatelet	No	2503	0.89 (0.84–0.95)	<0.001	0.84 (0.77–0.92)	0.081	2513	0.75 (0.71–0.80)	0.011	0.72 (0.67–0.77)	0.220
	Yes	498	0.69 (0.61–0.78)		0.73 (0.62–0.85)		620	0.62 (0.55–0.71)		0.66 (0.58–0.75)	
Prior MI or stroke	No	2603	0.88 (0.83–0.93)	0.004	0.87 (0.80–0.95)	<0.0001	2680	0.74 (0.70–0.79)	0.021	0.72 (0.67–0.77)	0.086
	Yes	398	0.71 (0.62–0.82)		0.58 (0.48–0.69)		453	0.62 (0.53–0.72)		0.63 (0.55–0.73)	
Prior diabetes	No	2363	0.88 (0.83–0.93)	0.053	0.85 (0.78–0.93)	0.034	2456	0.74 (0.70–0.79)	0.149	0.71 (0.66–0.76)	0.639
	Yes	638	0.78 (0.70–0.87)		0.72 (0.62–0.83)		677	0.67 (0.60–0.76)		0.69 (0.61–0.78)	

Supplementary table 2 (b) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with arterial events 1-28 and >28 days after vaccination, within pre-specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

		ChAdOx1-S vaccine					BNT162b2 vaccine				
		N (Events)	Post vaccination ≤28 days		Post vaccination >28 days		N (Events)	Post vaccination ≤28 days		Post vaccination >28 days	
Subgroup	**All arterial**	**12890**	HR (95% CI)[1]	P value	HR (95% CI)[1]	P value	**16759**	HR (95% CI)[1]	P value	HR (95% CI)[1]	P value
Age groups	18-29	12	1.72 (0.89–3.33)	<0.0001	1.84 (0.59–5.73)	0.031	21	2.01 (1.13–3.57)	<0.0001	1.85 (0.96–3.59)	<0.0001
	30-39	54	1.51 (1.11–2.06)		1.54 (0.87–2.72)		67	1.36 (1.00–1.86)		1.09 (0.74–1.61)	
	40-49	277	1.37 (1.20–1.57)		1.29 (0.99–1.69)		284	1.17 (1.01–1.36)		0.86 (0.70–1.05)	
	50-59	963	0.98 (0.91–1.05)		0.89 (0.76–1.04)		1062	1.06 (0.98–1.14)		0.81 (0.72–0.91)	
	60-69	2442	0.85 (0.81–0.90)		0.90 (0.82–0.99)		1705	0.89 (0.84–0.95)		0.83 (0.76–0.92)	
	70-79	5030	0.90 (0.86–0.94)		0.93 (0.88–0.99)		3993	0.85 (0.81–0.89)		0.91 (0.86–0.96)	
	80-89	2826	0.86 (0.81–0.91)		0.88 (0.82–0.94)		7733	0.74 (0.71–0.78)		0.79 (0.76–0.82)	
	>90	1286	0.85 (0.78–0.93)		0.86 (0.78–0.94)		1894	0.72 (0.66–0.79)		0.78 (0.73–0.84)	
Sex	Male	7116	0.78 (0.75–0.80)	<0.0001	0.75 (0.71–0.79)	<0.0001	9292	0.77 (0.74–0.79)	<0.0001	0.71 (0.68–0.73)	<0.0001
	Female	5774	0.89 (0.86–0.93)		0.87 (0.83–0.92)		7467	0.85 (0.82–0.88)		0.89 (0.85–0.92)	
Ethnicity	White	11729	0.82 (0.79–0.84)	<0.0001	0.80 (0.77–0.84)	0.180	15492	0.80 (0.78–0.82)	<0.0001	0.79 (0.76–0.81)	<0.0001
	Asian or Asian British	647	0.84 (0.76–0.93)		0.74 (0.64–0.86)		728	0.75 (0.67–0.84)		0.63 (0.56–0.71)	
	Black or Black British	217	0.90 (0.75–1.07)		0.89 (0.70–1.15)		190	0.77 (0.62–0.94)		0.79 (0.64–0.99)	
	Mixed	72	1.19 (0.90–1.57)		0.56 (0.32–0.98)		85	1.10 (0.82–1.49)		0.81 (0.57–1.17)	
	Other Ethnic Groups	113	0.93 (0.73–1.18)		0.90 (0.64–1.28)		121	0.89 (0.69–1.15)		0.76 (0.57–1.01)	
	Unknown	80	0.88 (0.67–1.16)		0.75 (0.49–1.16)		103	0.87 (0.64–1.18)		1.09 (0.83–1.44)	
	Missing	32	3.01 (1.98–4.57)		1.91 (0.89–4.08)		40	2.87 (1.81–4.56)		2.87 (1.80–4.58)	
Deprivation	1-2 (least)	2498	0.76 (0.71–0.80)	<0.001	0.71 (0.66–0.77)	<0.0001	2788	0.75 (0.71–0.79)	<0.0001	0.69 (0.65–0.73)	<0.0001
	3-4	2514	0.81 (0.76–0.85)		0.76 (0.71–0.82)		2980	0.76 (0.72–0.81)		0.74 (0.69–0.78)	
	5-6	2683	0.85 (0.81–0.90)		0.79 (0.74–0.85)		3489	0.78 (0.74–0.83)		0.79 (0.75–0.84)	
	7-8	2616	0.83 (0.78–0.87)		0.86 (0.80–0.92)		3693	0.82 (0.78–0.87)		0.83 (0.79–0.88)	
	9-10 (most)	2541	0.89 (0.85–0.95)		0.88 (0.82–0.95)		3772	0.90 (0.85–0.95)		0.85 (0.80–0.89)	
Prior thrombocytopenia	No	12889	0.82 (0.80–0.85)	0.334	0.80 (0.77–0.84)	0.499	16758	0.80 (0.78–0.82)	0.920	0.78 (0.76–0.81)	0.136
	Yes	<5	0.75 (0.61–0.91)		0.73 (0.57–0.95)		<5	0.81 (0.66–1.00)		0.67 (0.54–0.82)	
Prior thrombophilia	No	12864	0.82 (0.80–0.85)	0.059	0.80 (0.77–0.83)	0.620	16735	0.80 (0.78–0.82)	0.499	0.78 (0.76–0.81)	0.098
	Yes	26	0.48 (0.28–0.84)		0.66 (0.32–1.39)		24	0.66 (0.38–1.15)		0.43 (0.21–0.88)	
Prior venous event	No	12874	0.83 (0.81–0.85)	0.029	0.80 (0.77–0.84)	0.504	16751	0.81 (0.78–0.83)	0.022	0.79 (0.76–0.81)	0.002
	Yes	16	0.73 (0.66–0.82)		0.77 (0.67–0.88)		8	0.70 (0.63–0.79)		0.66 (0.59–0.74)	
Prior COVID infection	No	12227	0.84 (0.81–0.86)	<0.0001	0.83 (0.79–0.86)	<0.0001	16234	0.81 (0.79–0.84)	<0.0001	0.80 (0.77–0.82)	<0.0001
	Yes	663	0.63 (0.57–0.70)		0.51 (0.45–0.59)		525	0.57 (0.50–0.65)		0.51 (0.45–0.59)	
OCP	No	12889	0.91 (0.79–1.05)	0.983	0.89 (0.67–1.18)	<0.0001	16759	0.91 (0.79–1.06)	<0.0001	0.94 (0.75–1.16)	<0.0001
	Yes	<5	0.89 (0.12–6.51)		0.00 (0.00–0.00)		0	0.00 (0.00–0.00)		0.00 (0.00–0.00)	
HRT	No	12832	0.85 (0.82–0.87)	0.293	0.84 (0.80–0.88)	0.820	16671	0.81 (0.78–0.83)	0.061	0.79 (0.76–0.81)	0.070
	Yes	58	1.01 (0.73–1.40)		0.79 (0.45–1.37)		88	1.10 (0.79–1.51)		1.08 (0.77–1.52)	
Anticoagulant	No	10726	0.84 (0.82–0.87)	<0.001	0.82 (0.78–0.85)	0.015	13715	0.83 (0.81–0.86)	<0.0001	0.80 (0.77–0.83)	<0.001
	Yes	2164	0.74 (0.69–0.79)		0.74 (0.68–0.80)		3044	0.66 (0.62–0.70)		0.71 (0.67–0.76)	
Antiplatelet	No	7636	0.99 (0.96–1.03)	<0.0001	1.06 (1.01–1.11)	<0.0001	9770	0.96 (0.93–0.99)	<0.0001	1.05 (1.01–1.09)	<0.0001
	Yes	5254	0.65 (0.63–0.68)		0.59 (0.55–0.62)		6989	0.65 (0.63–0.67)		0.55 (0.53–0.57)	
Prior MI or stroke	No	6931	1.09 (1.05–1.13)	<0.0001	1.18 (1.12–1.24)	<0.0001	9428	1.08 (1.04–1.12)	<0.0001	1.22 (1.17–1.26)	<0.0001
	Yes	5959	0.64 (0.61–0.66)		0.60 (0.57–0.63)		7331	0.60 (0.57–0.62)		0.51 (0.49–0.53)	
Prior diabetes	No	8742	0.85 (0.83–0.88)	<0.0001	0.84 (0.80–0.88)	<0.001	11689	0.84 (0.82–0.87)	<0.0001	0.82 (0.79–0.85)	<0.0001
	Yes	4148	0.77 (0.73–0.80)		0.73 (0.69–0.78)		5070	0.72 (0.69–0.76)		0.70 (0.67–0.74)	

Supplementary table 3. Characteristics of patient who had an ICVT event before and after vaccination. Only percentage are presented, as disclosure control does not allow numbers <5 to be released

		ICVT before vaccination %	ICVT after ChAdOx1, %	ICVT after BNT162b, %	p-value[1]
N		<210	<40	<20	<0.0001
Sex	Male	40	33	21	0.24
	Female	60	67	79	
Age	18 - 29	19	17	0	<0.0001
	30 - 49	42	22	26	
	50 - 69	30	36	16	
	70 - 79	6	11	21	
	80+	3	14	37	
Ethnicity	Asian or Asian British	15	6	0	0.38
	Black or Black British	5	3	0	
	Mixed	2	0	0	
	Other ethnic groups	1	0	0	
	White	75	92	100	
	Unknown or missing	1	0	0	
Deprivation[2]	1 - 2	29	17	11	0.19
	3 - 4	20	14	26	
	5 - 6	25	25	21	
	7 - 8	13	25	16	
	9 - 10	13	19	26	
Smoking status	Current	19	28	11	0.5
	Former	21	17	32	
	Never	57	56	58	
Medical history	Stroke	5	6	11	<0.0001
	MI	3	6	0	0.01
	DVT or PE	8	6	5	<0.0001
	Thrombophilia	1	0	0	0.05
	Coronavirus infection[3]	6	6	0	<0.0001
	Diabetes	10	17	37	<0.0001
	Depression	26	36	16	<0.0001
	Obesity	37	31	42	<0.0001
	Cancer	17	28	37	<0.0001
	COPD	2	11	16	0.78
	Liver disease	<1	3	0	0.61
	CKD	5	11	32	0.25
	Major surgery[4]	18	8	11	<0.0001
	Dementia	2	3	0	0.03
Medications	Antiplatelet	5	6	16	0.01
	BP lowering	15	28	42	<0.0001
	Lipid lowering	12	22	26	<0.0001
	Anticoagulant	10	11	11	<0.0001
	Oral contraceptive	4	0	0	<0.0001
	HRT	1	0	0	0.05
Number of diagnoses[5]	0	71	50	58	0.04
	1 - 5	29	50	42	
Number of medications	0	31	11	2	0.02
	1 - 5	62	83	5	
	6+	7	6	2	

[1] Approximation if Chi squared test included one or more zero counts; [2] Index of Multiple Deprivation deciles where 1 indicates least deprived and 10 indicates most deprived; [3] After 31/12/2019 and prior to 08/12/2020; [4] In the last year; [5] The category '6+' contained no individuals and so was excluded.



Supplementary figure 1: Cumulative incidence of vaccines of different types during follow up



Supplementary figure 2: Adjusted hazard ratios for portal vein thrombosis, other venous events, and death after ChAdOx1-S or BNT162b2 vaccine